Subscribe

Merck & Co., Inc. (MRK)

USD124.03 +0.49 (+0.40%)
US NYSE DJIA S&P 500 Healthcare Drug Manufacturers - General
Address 126 East Lincoln Avenue 7065
Rahway, NJ, US
CEO Robert Davis
Website merck.com
IPO 1978-01-13
CIK 310158 ISIN US58933Y1055

Explore sections of this company profile

Also trades on Deutsche Börse · 6MK.DE (EUR) Euronext Paris · MRK.PA (EUR) London Stock Exchange · 0QAH.L (USD) New York Stock Exchange · MRK (USD)
Description

Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.

News Sentiment (7d)
68 Positive

5 articles

Market Cap & Enterprise Value
Merger & Acquisition History
Target company Ticker Date Filing
Schering SGP 1995-12-18 View

Index membership

IndexAddedRemovedStatus
DJIA 1994-01-01 — Active
S&P 500 1957-03-04 — Active
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
USD124.03 +0.49 (+0.40%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
10M
Beta
0.22
Float Shares
2.47B
Free Float %
99.9%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-0.07% -1.95% -8.33% -6.66% +21.71% +5.74% +38.38% -4.99% +49.66% +115.70% +28,050.85%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Analyst Consensus (37 ratings, all time) Buy
Price Targets & DCF
Current price
124.03
Low 100.00 -19.4%
Consensus 129.31 +4.3%
Median 133.00 +7.2%
High 150.00 +20.9%
DCF (Unlevered) 232.37 +87.4%
DCF (Levered) 131.28 +5.8%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 66% Bullish
Rating 2026-05 Change
Strong Buy 4 0
Buy 15 0
Hold 10 -1
Sell 0 0
Strong Sell 0 0
Price Target Summary
Period # Analysts Avg Target
Last Month 1
112.00
-9.7%
Last Quarter 4
138.50
+11.7%
Last Year 20
122.05
-1.6%
All Time 64
115.66
-6.7%
Quality scores
Altman Z-Score
3.80
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
4 / 5
High
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
1 / 5
Low
P/E Score
2 / 5
Medium
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Drug Manufacturers - General: +6.6%
    +1.2% Q1'26: +4.3% (vs Q1'25)
  • ✓
    EPS growth Drug Manufacturers - General: +18.2%
    +8.0% Q1'26: -185.6% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Drug Manufacturers - General: +36.0%
    +21.7% Q1'26: +18.0% (vs Q1'25)
  • ✓
    EBIT margin Drug Manufacturers - General: +19.4%
    +36.2% ★ Q1'26: -11.6% (vs Q1'25)
  • ✓
    ROIC Drug Manufacturers - General: +10.2%
    +23.0% ★ Q1'26: -8.4% (vs Q1'25)
  • ✓
    Share dilution Drug Manufacturers - General: +0.0%
    -1.3% ★ Q1'26: -2.3% (vs Q1'25)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×
    1.72× Q1'26: -6.52× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.20) × ERP
WACC = 85% × Ke + 15% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 232.37 Current price: 124.03
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2010
actual 		Dec 2011
actual 		Dec 2013
actual 		Dec 2014
actual 		Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
7 Rev. Ana.
6 EPS Ana. 		Dec 2027
7 Rev. Ana.
6 EPS Ana. 		Dec 2028
5 Rev. Ana.
3 EPS Ana. 		Dec 2029
2 Rev. Ana.
1 EPS Ana. 		Dec 2030
2 Rev. Ana.
1 EPS Ana.
Revenue
45.99B
est: 43.41B (+5.9%)
48.05B
est: 46.40B (+3.5%)
44.03B
est: 42.80B (+2.9%)
42.24B
est: 40.32B (+4.8%)
39.50B
est: 39.59B (-0.2%)
39.81B
est: 39.98B (-0.4%)
40.12B
est: 40.20B (-0.2%)
42.29B
est: 42.24B (+0.1%)
39.12B
est: 46.90B (-16.6%)
41.52B
est: 48.19B (-13.8%)
48.70B
est: 48.52B (+0.4%)
59.28B
est: 59.12B (+0.3%)
60.12B
est: 62.48B (-3.8%)
64.17B
est: 63.99B (+0.3%)
64.93B
est: 64.85B (+0.1%)
66.71B
66.45B – 67.03B
+2.9% YoY
70.16B
68.90B – 71.83B
+5.2% YoY
74.90B
74.48B – 75.32B
+6.8% YoY
74.89B
73.76B – 76.11B
0.0% YoY
74.40B
73.28B – 75.61B
-0.7% YoY
EBITDA
9.75B
est: 9.08B (+7.4%)
15.46B
est: 14.81B (+4.3%)
13.33B
est: 12.81B (+4.1%)
24.71B
est: 23.82B (+3.7%)
12.45B
est: 11.61B (+7.2%)
10.82B
est: 10.20B (+6.1%)
11.95B
est: 10.82B (+10.4%)
13.99B
est: 13.57B (+3.1%)
11.37B
est: 14.12B (-19.4%)
10.18B
est: 10.17B (+0.1%)
17.90B
est: 17.66B (+1.4%)
21.32B
est: 19.59B (+8.8%)
6.91B
est: 33.75B (-79.5%)
25.71B
est: 34.56B (-25.6%)
29.32B
est: 35.03B (-16.3%)
36.03B
35.89B – 36.20B
+2.9% YoY
37.89B
37.21B – 38.79B
+5.2% YoY
40.45B
40.23B – 40.68B
+6.8% YoY
40.45B
39.84B – 41.11B
0.0% YoY
40.18B
39.58B – 40.84B
-0.7% YoY
EBIT
2.37B
est: 3.18B (-25.5%)
8.08B
est: 8.65B (-6.5%)
6.35B
est: 7.42B (-14.4%)
18.02B
est: 6.32B (+184.9%)
6.07B
est: 7.09B (-14.4%)
5.35B
est: 5.66B (-5.5%)
7.28B
est: 6.63B (+9.7%)
9.47B
est: 8.66B (+9.3%)
12.36B
est: 10.72B (+15.3%)
6.69B
est: 6.23B (+7.4%)
14.69B
est: 12.88B (+14.0%)
17.41B
est: 17.34B (+0.4%)
3.04B
est: 27.00B (-88.8%)
21.21B
est: 27.65B (-23.3%)
23.49B
est: 28.03B (-16.2%)
28.83B
28.72B – 28.97B
+2.9% YoY
30.32B
29.78B – 31.04B
+5.2% YoY
32.37B
32.19B – 32.55B
+6.8% YoY
32.37B
31.88B – 32.90B
0.0% YoY
32.15B
31.67B – 32.68B
-0.7% YoY
Net Income
861.00M
est: 821.95M (+4.8%)
6.27B
est: 6.08B (+3.1%)
4.40B
est: 4.23B (+4.1%)
11.92B
est: 11.52B (+3.5%)
4.44B
est: 4.17B (+6.5%)
3.92B
est: 3.66B (+7.0%)
2.39B
est: 2.04B (+17.5%)
6.22B
est: 6.03B (+3.1%)
9.84B
est: 8.65B (+13.9%)
7.07B
est: 5.03B (+40.6%)
13.05B
est: 12.27B (+6.4%)
14.52B
est: 14.91B (-2.6%)
365.00M
est: 13.74B (-97.3%)
17.12B
est: 18.92B (-9.5%)
18.25B
est: 22.44B (-18.6%)
10.78B
7.65B – 13.91B
-52.0% YoY
23.97B
23.19B – 24.75B
+122.3% YoY
23.38B
23.26B – 29.03B
-2.5% YoY
26.15B
25.64B – 26.70B
+11.8% YoY
25.38B
24.89B – 25.92B
-2.9% YoY
SGA
13.13B
est: 12.42B (+5.6%)
13.73B
est: 13.24B (+3.7%)
11.91B
est: 11.55B (+3.1%)
11.61B
est: 11.05B (+5.1%)
10.31B
est: 9.64B (+7.0%)
10.02B
est: 9.41B (+6.5%)
10.07B
est: 9.00B (+12.0%)
10.10B
est: 9.77B (+3.4%)
9.46B
est: 9.33B (+1.3%)
8.57B
est: 9.03B (-5.1%)
9.40B
est: 9.68B (-2.9%)
9.67B
est: 8.99B (+7.5%)
9.88B
est: 10.54B (-6.2%)
10.10B
est: 10.79B (-6.4%)
10.73B
est: 10.94B (-1.9%)
11.25B
11.21B – 11.30B
+2.9% YoY
11.83B
11.62B – 12.11B
+5.2% YoY
12.63B
12.56B – 12.70B
+6.8% YoY
12.63B
12.44B – 12.84B
0.0% YoY
12.55B
12.36B – 12.75B
-0.7% YoY
EPS
0.28
est: 3.04 (-90.8%)
2.06
est: 3.52 (-41.5%)
1.50
est: 3.29 (-54.4%)
4.20
est: 3.18 (+32.1%)
1.60
est: 3.41 (-53.0%)
2.07
est: 3.60 (-42.6%)
0.95
est: 3.76 (-74.7%)
2.40
est: 4.13 (-41.9%)
3.84
est: 4.93 (-22.1%)
2.79
est: 5.72 (-51.2%)
5.16
est: 5.79 (-10.9%)
5.73
est: 7.39 (-22.5%)
0.14
est: 5.42 (-97.4%)
6.76
est: 7.53 (-10.2%)
7.30
est: 8.93 (-18.3%)
5.14
3.05 – 5.55
-42.5% YoY
9.64
9.25 – 9.87
+87.7% YoY
10.72
9.28 – 11.58
+11.2% YoY
10.43
10.23 – 10.65
-2.7% YoY
10.12
9.93 – 10.34
-2.9% YoY
Recent Grade Changes (3M)
Date Firm Previous New Grade Action
2026-05-01 Wells Fargo Overweight Overweight Maintain
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-11 B+ 3/5 4/5 5/5 5/5 1/5 2/5 1/5
2026-05-08 B+ 3/5 4/5 5/5 5/5 1/5 2/5 1/5
2026-05-07 B+ 3/5 4/5 5/5 5/5 1/5 2/5 1/5
2026-05-06 B+ 3/5 4/5 5/5 5/5 1/5 2/5 1/5
2026-05-05 B+ 3/5 4/5 5/5 5/5 1/5 2/5 1/5
2026-05-04 B+ 3/5 4/5 5/5 5/5 1/5 2/5 1/5
2026-05-01 C 2/5 4/5 1/5 1/5 1/5 2/5 1/5
2026-04-30 A- 4/5 4/5 5/5 5/5 1/5 3/5 2/5
2026-04-29 A- 4/5 4/5 5/5 5/5 1/5 3/5 2/5
2026-04-28 A- 4/5 4/5 5/5 5/5 1/5 3/5 2/5
2026-04-27 A- 4/5 4/5 5/5 5/5 1/5 3/5 2/5
2026-04-24 A- 4/5 4/5 5/5 5/5 1/5 3/5 2/5
2026-04-23 A- 4/5 4/5 5/5 5/5 1/5 3/5 2/5
2026-04-22 A- 4/5 4/5 5/5 5/5 1/5 3/5 2/5
2026-04-21 A- 4/5 4/5 5/5 5/5 1/5 3/5 2/5
2026-04-20 A- 4/5 4/5 5/5 5/5 1/5 3/5 2/5
2026-04-17 A- 4/5 4/5 5/5 5/5 1/5 3/5 2/5
2026-04-16 A- 4/5 4/5 5/5 5/5 1/5 3/5 2/5
2026-04-15 A- 4/5 4/5 5/5 5/5 1/5 3/5 2/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
12.65B
OE per share TTM
5.06
Owner's Yield
4.60%
Maintenance CapEx ratio
25.71%
Maint CapEx / Avg PPE
38.7%

Ownership Overview

Ownership breakdown
At a glance
Institutional holders
1,788
Total invested
17.33B
Insider transactions (90d)
13
Beneficial owners (>5%)
21
Beneficial owners (>5%)
# Reporting person ⇅ Amount owned ⇅ % of class ⇅ Sole voting ⇅ Shared voting ⇅ Sole dispositive ⇅ Shared dispositive ⇅ Type Citizenship Filing date ⇅ SEC filing
1 The Vanguard Group - 23-1945930 210.54M 8.26% 3.94M 747.6K 206.09M 4.46M IA Pennsylvania 2020-02-12 ↗
2 (1) BlackRock, Inc. 198.22M 7.80% 171.96M — 198.22M — HC Delaware 2022-02-01 ↗
3 BlackRock for purposes of Schedule 13G filings. 161.49M 5.29% 161.49M — 161.49M — HC Delaware 2010-01-29 ↗
4 04-2683227 154.02M 5.27% — 46.33M — — IA Massachusetts 2014-02-14 ↗
5 Wellington Group Holdings LLP 124.19M 4.50% — 28.26M — — HC Delaware 2017-02-09 ↗
6 Wellington Investment Advisors Holdings LLP 124.19M 4.50% — 28.26M — — HC Delaware 2017-02-09 ↗
7 Wellington Management Group LLP 124.19M 4.50% — 28.26M — — HC Massachusetts 2017-02-09 ↗
8 94-1441976 58.26M 3.90% — — — — IA U.S.A. 2006-02-03 ↗
9 Inc. 31.59M 7.40% — 31.59M — — HC Switzerland 2016-02-12 ↗
10 22-1918501 22.91M 27.50% — 22.91M — — CO New Jersey 2011-04-15 ↗
11 45-1540007 22.91M 27.50% — 22.91M — — CO Delaware 2011-04-15 ↗
12 IMPERIAL BLUE CORPORATION 22.48M 14.90% — 22.48M — 10.00 CO DELAWARE 2014-06-13 ↗
13 ARGON MERGER SUB, INC. 17.48M 12.60% — 17.48M — 10.00 CO DELAWARE 2019-12-16 ↗
14 MERCK & CO., INC. 11.78M 39.99% — 11.78M — 11.78M HC, CO — 2021-03-04 ↗
15 MERCK SHARP & DOHME CORP. 11.78M 39.99% — 11.78M — 11.78M HC, CO — 2021-03-04 ↗
16 PANAMA MERGER SUB, INC. 11.78M 39.99% — 11.78M — 11.78M CO — 2021-03-04 ↗
17 Merck Global Health Innovation Fund, LLC 4.60M 11.40% — 4.60M — 4.60M OO New Jersey 2024-01-23 ↗
18 MRL Ventures Fund LLC 3.55M 5.10% 3.55M — 3.55M — OO Delaware 2019-02-14 ↗
19 1,070,589 shares 1.07M 9.90% — 1.07M — 1.07M HC New Jersey 2017-10-16 ↗
20 9.9%* 1.07M 9.90% — 1.07M — 1.07M CO New Jersey 2017-10-16 ↗
21 Merck Sharp & Dohme Research GmbH — 0.00% — — — — FI Switzerland 2018-02-13 ↗

Institutional Activity (13F)

Institutional ownership trend From To
13F snapshot — 2026 Q1
Investors holding
1,788
-1,932 vs prev Q
New positions
122
Closed positions
1,971
Increased
801
Reduced
749
Put/Call ratio
3.23
Calls held
63.1K
Puts held
203.7K
Top institutional holders
# Investor ⇅ Shares / Δ ⇅ Mkt value / Δ ⇅ Own% / Δ ⇅ Weight% / Δ ⇅ Avg px / Perf. ⇅ Hold / Status ⇅
1 VANGUARD GROUP INC 254.32M +2.2M (+0.9%) 26.77B +5.6B (+26.5%) 10.14% +0.070 pp 0.39% +0.071 pp USD56.31 +86.9% 65 qtrs —
2 BLACKROCK, INC. 219.10M +4.2M (+2.0%) 23.06B +5.0B (+27.9%) 8.74% +0.154 pp 0.39% +0.074 pp USD112.44 -6.4% 6 qtrs —
3 STATE STREET CORP 120.04M +1.9M (+1.6%) 12.74B +2.7B (+27.2%) 4.79% +0.066 pp 0.43% +0.080 pp USD54.86 +91.9% 51 qtrs —
4 WELLINGTON MANAGEMENT GROUP LLP 86.44M +11.2M (+14.8%) 9.10B +2.8B (+44.0%) 3.45% +0.440 pp 1.59% +0.488 pp USD87.13 +20.8% 65 qtrs —
5 GEODE CAPITAL MANAGEMENT, LLC 60.05M +249.1K (+0.4%) 6.31B +1.3B (+26.0%) 2.39% +0.006 pp 0.39% +0.070 pp USD69.33 +51.8% 65 qtrs —
6 CHARLES SCHWAB INVESTMENT MANAGEMENT INC 48.56M -5.1M (-9.6%) 5.11B +604.8M (+13.4%) 1.94% -0.209 pp 0.79% +0.075 pp USD84.33 +24.8% 65 qtrs —
7 MORGAN STANLEY 44.95M +359.5K (+0.8%) 4.73B +988.9M (+26.4%) 1.79% +0.011 pp 0.28% +0.056 pp USD83.22 +26.5% 51 qtrs —
8 FMR LLC 40.84M +7.4M (+22.2%) 4.30B +1.5B (+53.2%) 1.63% +0.293 pp 0.22% +0.073 pp USD100.25 +5.0% 65 qtrs —
9 NORGES BANK 37.98M +38.0M (+100.0%) 4.00B +4.0B (+100.0%) 1.51% +1.515 pp 0.43% +0.428 pp USD105.26 +0.0% 1 qtrs NEW
10 JPMORGAN CHASE & CO 29.20M -6.0M (-17.0%) 3.07B +119.1M (+4.0%) 1.17% -0.234 pp 0.19% +0.016 pp USD82.77 +27.2% 51 qtrs —
11 BANK OF AMERICA CORP /DE/ 27.85M +1.4M (+5.3%) 2.93B +712.1M (+32.1%) 1.11% +0.054 pp 0.21% +0.063 pp USD70.15 +50.0% 52 qtrs —
12 NORTHERN TRUST CORP 27.23M -698.5K (-2.5%) 2.87B +522.3M (+22.3%) 1.09% -0.030 pp 0.37% +0.066 pp USD58.35 +80.4% 51 qtrs —
13 FISHER ASSET MANAGEMENT, LLC 24.87M +805.2K (+3.3%) 2.62B +598.1M (+29.6%) 0.99% +0.031 pp 0.89% +0.163 pp USD80.10 +31.4% 57 qtrs —
14 INVESCO LTD. 20.55M +701.2K (+3.5%) 2.16B +497.1M (+29.8%) 0.82% +0.027 pp 0.33% +0.069 pp USD77.84 +35.2% 57 qtrs —
15 LEGAL & GENERAL GROUP PLC 19.78M -882.3K (-4.3%) 2.08B +347.8M (+20.1%) 0.79% -0.037 pp 0.46% +0.073 pp USD61.38 +71.5% 65 qtrs —
16 UBS ASSET MANAGEMENT AMERICAS INC 19.43M -316.5K (-1.6%) 2.05B +388.0M (+23.4%) 0.78% -0.014 pp 0.43% +0.073 pp USD83.93 +25.4% 65 qtrs —
17 GOLDMAN SACHS GROUP INC 19.35M +4.3M (+28.8%) 2.04B +775.9M (+61.5%) 0.78% +0.177 pp 0.25% +0.096 pp USD91.10 +15.5% 65 qtrs —
18 UBS GROUP AG 19.18M +2.3M (+13.4%) 2.02B +599.8M (+42.3%) 0.76% +0.090 pp 0.33% +0.105 pp USD88.29 +19.2% 45 qtrs —
19 BANK OF NEW YORK MELLON CORP 19.16M -2.6M (-12.1%) 2.02B +188.1M (+10.3%) 0.76% -0.106 pp 0.36% +0.004 pp USD76.61 +37.4% 65 qtrs —
20 PRICE T ROWE ASSOCIATES INC /MD/ 18.75M +5.2M (+37.9%) 1.97B +832.4M (+72.9%) 0.75% +0.205 pp 0.21% +0.091 pp USD92.27 +14.1% 65 qtrs —
21 FRANKLIN RESOURCES INC 16.06M -682.9K (-4.1%) 1.69B +285.3M (+20.3%) 0.64% -0.028 pp 0.41% +0.064 pp USD97.21 +8.3% 51 qtrs —
22 AMERIPRISE FINANCIAL INC 15.97M +40.5K (+0.3%) 1.68B +346.2M (+25.9%) 0.64% +0.001 pp 0.38% +0.073 pp USD70.07 +50.2% 55 qtrs —
23 HARRIS ASSOCIATES L P 14.09M +4.3M (+43.4%) 1.48B +658.5M (+79.9%) 0.56% +0.169 pp 1.87% +0.553 pp USD100.16 +5.1% 6 qtrs —
24 STATE FARM MUTUAL AUTOMOBILE INSURANCE CO 13.79M +— (+0.0%) 1.45B +294.2M (+25.4%) 0.55% -0.001 pp 1.14% +0.175 pp USD34.84 +202.1% 65 qtrs —
25 AMUNDI 13.39M -1.8M (-12.0%) 1.41B +58.2M (+4.3%) 0.53% -0.074 pp 0.38% -0.051 pp USD90.34 +16.5% 19 qtrs —
26 ROYAL BANK OF CANADA 13.19M +381.7K (+3.0%) 1.39B +313.4M (+29.2%) 0.53% +0.014 pp 0.23% +0.050 pp USD83.38 +26.2% 51 qtrs —
27 DEUTSCHE BANK AG\ 12.79M -4.1M (-24.1%) 1.35B -67.8M (-4.8%) 0.51% -0.159 pp 0.44% -0.035 pp USD68.62 +53.4% 50 qtrs —
28 DIMENSIONAL FUND ADVISORS LP 12.49M +1.6M (+14.8%) 1.31B +401.9M (+44.0%) 0.50% +0.067 pp 0.28% +0.080 pp USD87.74 +20.0% 51 qtrs —
29 AQR CAPITAL MANAGEMENT LLC 11.25M +591.3K (+5.5%) 1.18B +332.7M (+39.1%) 0.45% +0.023 pp 0.62% +0.075 pp USD88.53 +18.9% 65 qtrs —
30 WELLS FARGO & COMPANY/MN 11.05M +599.7K (+5.7%) 1.16B +286.0M (+32.6%) 0.44% +0.023 pp 0.21% +0.045 pp USD56.93 +84.9% 57 qtrs —
31 NORDEA INVESTMENT MANAGEMENT AB 10.57M -371.4K (-3.4%) 1.12B +238.4M (+27.2%) 0.42% -0.013 pp 0.96% +0.190 pp USD78.93 +33.4% 65 qtrs —
32 ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 9.94M -8.8M (-46.8%) 1.05B -523.5M (-33.3%) 0.40% -0.351 pp 0.61% -0.377 pp USD89.34 +17.8% 36 qtrs —
33 SUSQUEHANNA INTERNATIONAL GROUP, LLP 9.05M +2.9M (+46.0%) 952.52M +432.3M (+83.1%) 0.36% +0.113 pp 0.11% +0.050 pp USD97.49 +8.0% 51 qtrs —
34 ALLIANCEBERNSTEIN L.P. 8.63M +402.6K (+4.9%) 908.64M +217.9M (+31.5%) 0.34% +0.016 pp 0.29% +0.069 pp USD87.18 +20.7% 61 qtrs —
35 CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 8.57M +1.0M (+13.2%) 901.91M +266.9M (+42.0%) 0.34% +0.042 pp 0.52% +0.136 pp USD69.24 +52.0% 53 qtrs —
36 STIFEL FINANCIAL CORP 8.55M -173.8K (-2.0%) 899.67M +167.7M (+22.9%) 0.34% -0.008 pp 0.81% +0.141 pp USD75.58 +39.3% 48 qtrs —
37 HSBC HOLDINGS PLC 8.08M -312.4K (-3.7%) 850.55M +148.7M (+21.2%) 0.32% -0.011 pp 0.43% +0.046 pp USD97.93 +7.5% 56 qtrs —
38 BARROW HANLEY MEWHINNEY & STRAUSS LLC 7.79M +377.9K (+5.1%) 820.31M +197.9M (+31.8%) 0.31% +0.015 pp 2.73% +0.750 pp USD82.58 +27.5% 57 qtrs —
39 SWEDBANK AB 7.65M -692.5K (-8.3%) 805.41M +105.1M (+15.0%) 0.31% -0.028 pp 0.78% +0.069 pp USD90.54 +16.3% 20 qtrs —
40 PNC FINANCIAL SERVICES GROUP, INC. 7.62M -246.1K (-3.1%) 802.27M +141.9M (+21.5%) 0.30% -0.010 pp 0.44% +0.038 pp USD51.00 +106.4% 51 qtrs —
41 DEKABANK DEUTSCHE GIROZENTRALE 5.43M +— (+0.0%) 774.02M +349.3M (+82.2%) 0.22% 0.000 pp 1.34% +0.623 pp USD77.21 +36.3% 65 qtrs —
42 ARISTOTLE CAPITAL MANAGEMENT, LLC 7.28M -537.0K (-6.9%) 766.39M +110.2M (+16.8%) 0.29% -0.022 pp 1.53% +0.266 pp USD89.79 +17.2% 14 qtrs —
43 SUMITOMO MITSUI TRUST HOLDINGS, INC. 6.97M -394.4K (-5.4%) 733.85M +115.6M (+18.7%) 0.28% -0.014 pp 0.43% +0.075 pp USD61.74 +70.5% 59 qtrs —
44 NUVEEN, LLC 6.96M +50.0K (+0.7%) 732.41M +152.6M (+26.3%) 0.28% +0.002 pp 0.19% +0.039 pp USD89.87 +17.1% 4 qtrs —
45 RAYMOND JAMES FINANCIAL INC 6.93M -78.8K (-1.1%) 729.44M +141.3M (+24.0%) 0.28% -0.004 pp 0.23% +0.038 pp USD99.48 +5.8% 5 qtrs —
46 GRANTHAM, MAYO, VAN OTTERLOO & CO. LLC 6.87M +244.8K (+3.7%) 723.15M +167.1M (+30.0%) 0.27% +0.009 pp 1.85% +0.280 pp USD91.31 +15.3% 38 qtrs —
47 SWISS NATIONAL BANK 6.84M -394.8K (-5.5%) 720.34M +112.8M (+18.6%) 0.27% -0.016 pp 0.43% +0.076 pp USD60.98 +72.6% 51 qtrs —
48 CITADEL ADVISORS LLC 6.82M +5.9M (+604.6%) 718.01M +636.8M (+783.7%) 0.27% +0.233 pp 0.11% +0.096 pp USD102.23 +3.0% 52 qtrs —
49 MILLENNIUM MANAGEMENT LLC 6.80M +6.0M (+790.8%) 715.80M +651.7M (+1,017.2%) 0.27% +0.241 pp 0.30% +0.274 pp USD105.52 -0.2% 65 qtrs —
50 NATIONAL PENSION SERVICE 5.79M +82.0K (+1.4%) 609.39M +130.4M (+27.2%) 0.23% +0.003 pp 0.45% +0.079 pp USD79.18 +32.9% 46 qtrs —
51 JENNISON ASSOCIATES LLC 5.56M +5.6M (+100.0%) 585.19M +585.2M (+100.0%) 0.22% +0.223 pp 0.35% +0.351 pp USD105.26 +0.0% 1 qtrs NEW
52 MITSUBISHI UFJ KOKUSAI ASSET MANAGEMENT CO., LTD. 5.41M +238.5K (+4.6%) 576.08M +141.7M (+32.6%) 0.22% +0.011 pp 0.39% +0.078 pp USD95.65 +10.0% 58 qtrs —
53 BANK OF MONTREAL /CAN/ 5.37M -26.1K (-0.5%) 565.48M +112.4M (+24.8%) 0.21% -0.001 pp 0.20% +0.022 pp USD88.69 +18.7% 51 qtrs —
54 AMERICAN CENTURY COMPANIES INC 5.37M +809.0K (+17.7%) 565.10M +182.4M (+47.7%) 0.21% +0.032 pp 0.28% +0.089 pp USD92.87 +13.3% 51 qtrs —
55 LSV ASSET MANAGEMENT 5.17M -124.8K (-2.4%) 544.66M +99.9M (+22.5%) 0.21% -0.005 pp 1.19% +0.206 pp USD59.79 +76.0% 59 qtrs —
56 PRINCIPAL FINANCIAL GROUP INC 5.08M -126.6K (-2.4%) 535.01M +97.8M (+22.4%) 0.20% -0.004 pp 0.27% +0.053 pp USD62.60 +68.1% 65 qtrs —
57 CAPITAL WEALTH PLANNING, LLC 5.00M +1.8M (+56.8%) 529.23M +261.4M (+97.6%) 0.20% +0.072 pp 3.43% +1.538 pp USD90.16 +16.7% 50 qtrs —
58 VICTORY CAPITAL MANAGEMENT INC 4.81M +75.2K (+1.6%) 506.15M +108.9M (+27.4%) 0.19% +0.003 pp 0.29% +0.053 pp USD87.69 +20.0% 50 qtrs —
59 BARCLAYS PLC 4.77M -2.1M (-30.7%) 502.48M -279.7M (-35.8%) 0.19% -0.085 pp 0.12% -0.080 pp USD111.45 -5.6% 51 qtrs —
60 JANE STREET GROUP, LLC 4.72M +2.5M (+112.6%) 497.04M +310.6M (+166.6%) 0.19% +0.101 pp 0.08% +0.047 pp USD98.73 +6.6% 6 qtrs —
61 ABRDN PLC 4.65M +171.4K (+3.8%) 489.56M +126.5M (+34.9%) 0.19% +0.008 pp 0.76% +0.184 pp USD89.75 +17.3% 34 qtrs —
62 FIRST TRUST ADVISORS LP 4.63M -383.3K (-7.6%) 487.18M +66.6M (+15.8%) 0.18% -0.016 pp 0.35% +0.041 pp USD84.65 +24.3% 51 qtrs —
63 MASSACHUSETTS FINANCIAL SERVICES CO /MA/ 4.42M -3.1M (-41.5%) 464.83M -168.8M (-26.6%) 0.18% -0.124 pp 0.15% -0.046 pp USD66.52 +58.2% 51 qtrs —
64 LAZARD ASSET MANAGEMENT LLC 4.41M -2.7M (-37.6%) 463.89M -129.0M (-21.8%) 0.18% -0.106 pp 0.79% -0.012 pp USD90.48 +16.3% 51 qtrs —
65 PACER ADVISORS, INC. 4.35M -885.8K (-16.9%) 458.03M +18.5M (+4.2%) 0.17% -0.035 pp 1.17% +0.063 pp USD89.08 +18.2% 41 qtrs —
66 CANADA PENSION PLAN INVESTMENT BOARD 4.31M +466.0K (+12.1%) 454.15M +131.1M (+40.6%) 0.17% +0.018 pp 0.30% +0.077 pp USD98.56 +6.8% 52 qtrs —
67 CAISSE DE DEPOT ET PLACEMENT DU QUEBEC 4.13M -635.6K (-13.3%) 434.88M +34.8M (+8.7%) 0.16% -0.026 pp 0.74% +0.017 pp USD95.27 +10.5% 51 qtrs —
68 BEUTEL, GOODMAN & CO LTD. 4.06M -790.3K (-16.3%) 427.61M +20.3M (+5.0%) 0.16% -0.032 pp 2.63% +0.174 pp USD89.48 +17.6% 33 qtrs —
69 RHUMBLINE ADVISERS 3.98M -124.1K (-3.0%) 418.54M +74.4M (+21.6%) 0.16% -0.005 pp 0.34% +0.062 pp USD59.93 +75.6% 51 qtrs —
70 MARSHALL WACE, LLP 3.97M +3.1M (+349.1%) 417.83M +343.6M (+463.2%) 0.16% +0.123 pp 0.38% +0.305 pp USD99.45 +5.8% 18 qtrs —
71 ALLIANZ ASSET MANAGEMENT GMBH 3.97M +733.9K (+22.7%) 417.55M +146.2M (+53.9%) 0.16% +0.029 pp 0.42% +0.119 pp USD84.48 +24.6% 51 qtrs —
72 CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM 3.95M -113.9K (-2.8%) 415.37M +74.6M (+21.9%) 0.16% -0.005 pp 0.42% +0.066 pp USD52.36 +101.0% 52 qtrs —
73 VAN ECK ASSOCIATES CORP 3.86M -1.5M (-27.4%) 406.76M -40.2M (-9.0%) 0.15% -0.059 pp 0.34% -0.079 pp USD92.58 +13.7% 57 qtrs —
74 HIGHTOWER ADVISORS, LLC 3.82M -51.0K (-1.3%) 401.90M +77.2M (+23.8%) 0.15% -0.001 pp 0.44% +0.071 pp USD71.84 +46.5% 65 qtrs —
75 THORNBURG INVESTMENT MANAGEMENT INC 3.73M +208.0K (+5.9%) 392.48M +97.0M (+32.8%) 0.15% +0.008 pp 4.95% +1.098 pp USD79.07 +33.1% 42 qtrs —
76 NEW YORK STATE COMMON RETIREMENT FUND 3.56M -111.9K (-3.1%) 374.31M +66.5M (+21.6%) 0.14% -0.005 pp 0.50% +0.102 pp USD39.03 +169.7% 65 qtrs —
77 LPL FINANCIAL LLC 3.56M +183.9K (+5.5%) 374.30M +91.3M (+32.3%) 0.14% +0.007 pp 0.10% +0.020 pp USD86.67 +21.4% 51 qtrs —
78 D. E. SHAW & CO., INC. 3.52M +50.6K (+1.5%) 370.35M +79.3M (+27.2%) 0.14% +0.002 pp 0.20% +0.039 pp USD102.65 +2.5% 65 qtrs —
79 RUSSELL INVESTMENTS GROUP, LTD. 3.21M -214.8K (-6.3%) 338.65M +54.5M (+19.2%) 0.13% -0.009 pp 0.37% +0.046 pp USD88.31 +19.2% 37 qtrs —
80 ENVESTNET ASSET MANAGEMENT INC 3.20M -191.7K (-5.6%) 337.29M +52.3M (+18.3%) 0.13% -0.008 pp 0.10% +0.018 pp USD95.99 +9.7% 51 qtrs —
81 ROYAL LONDON ASSET MANAGEMENT LTD 3.20M -2.7K (-0.1%) 336.53M +68.0M (+25.3%) 0.13% 0.000 pp 0.71% +0.131 pp USD85.03 +23.8% 31 qtrs —
82 BANK JULIUS BAER & CO. LTD, ZURICH 3.16M +100.3K (+3.3%) 333.57M +76.5M (+29.8%) 0.13% +0.005 pp 0.92% +0.196 pp USD102.58 +2.6% 24 qtrs —
83 LOS ANGELES CAPITAL MANAGEMENT LLC 3.85M +434.4K (+12.7%) 331.91M +45.5M (+15.9%) 0.15% +0.017 pp 1.13% +0.159 pp USD100.88 +4.3% 58 qtrs —
84 NEUBERGER BERMAN GROUP LLC 3.04M +427.9K (+16.4%) 320.03M +101.1M (+46.2%) 0.12% +0.017 pp 0.24% +0.078 pp USD87.01 +21.0% 51 qtrs —
85 VOYA INVESTMENT MANAGEMENT LLC 2.99M +2.3M (+335.5%) 314.36M +256.8M (+446.2%) 0.12% +0.092 pp 0.31% +0.252 pp USD97.37 +8.1% 51 qtrs —
86 GREAT WEST LIFE ASSURANCE CO /CAN/ 2.97M -722.9K (-19.6%) 312.81M +22.7M (+7.8%) 0.12% -0.029 pp 0.54% +0.129 pp USD73.23 +43.7% 63 qtrs —
87 AVIVA PLC 2.89M +115.0K (+4.1%) 303.92M +71.2M (+30.6%) 0.12% +0.004 pp 0.51% +0.090 pp USD90.34 +16.5% 51 qtrs —
88 SMEAD CAPITAL MANAGEMENT, INC. 2.84M -196.4K (-6.5%) 298.76M +44.1M (+17.3%) 0.11% -0.007 pp 6.20% +1.279 pp USD81.34 +29.4% 61 qtrs —
89 MARINER, LLC 2.75M +225.3K (+8.9%) 289.84M +77.7M (+36.6%) 0.11% +0.009 pp 0.35% +0.071 pp USD88.36 +19.1% 59 qtrs —
90 ADAGE CAPITAL PARTNERS GP, L.L.C. 2.69M +1.6M (+155.1%) 282.92M +194.5M (+219.9%) 0.11% +0.065 pp 0.43% +0.288 pp USD103.76 +1.4% 64 qtrs —
91 BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. 2.65M +1.7M (+171.4%) 279.47M +198.0M (+243.2%) 0.11% +0.067 pp 0.32% +0.110 pp USD100.98 +4.2% 51 qtrs —
92 CITIGROUP INC 2.64M -1.9M (-41.7%) 277.48M -102.1M (-26.9%) 0.11% -0.076 pp 0.12% -0.047 pp USD94.76 +11.1% 65 qtrs —
93 NATIXIS ADVISORS, L.P. 2.53M +217.3K (+9.4%) 266.05M +72.2M (+37.2%) 0.10% +0.009 pp 0.38% +0.094 pp USD85.01 +23.8% 57 qtrs —
94 — 2.51M +2.5M (+100.0%) 264.61M +264.6M (+100.0%) 0.10% +0.100 pp 0.82% +0.824 pp USD105.26 +0.0% 1 qtrs NEW
95 ROBECO INSTITUTIONAL ASSET MANAGEMENT B.V. 2.50M -508.2K (-16.9%) 262.94M +10.6M (+4.2%) 0.10% -0.020 pp 0.37% +0.009 pp USD78.22 +34.6% 65 qtrs —
96 ACTIAM N.V. 9.62M +9.6M (+100.0%) 101.25M +101.3M (+100.0%) 0.38% +0.384 pp 1.02% +1.024 pp USD105.26 +0.0% 1 qtrs NEW
Ownership breakdown by holder

Insider Activity

Insider Activity — Latest Quarter
Ratio by transactions
0.50
Neutral
Ratio by volume
0.68
Neutral
Buys
13
Sells
26
Shares acquired
49.6K
Shares disposed
72.9K
Cash buys
—
Cash sales
—
Net activity
-23,308
Insider buys vs sells (history) From To
Recent insider transactions From To
Date Person Role Transaction A/D Security Shares Price Value Owned after D/I Filing
2026-04-30 Smart Dalton E. III Officer M-Exempt D Restricted Stock Unit 464 0.00 — 465 D ↗
2026-04-30 Larson Betty D Officer M-Exempt A Common Stock 11,350 110.95 1.26M 18,917 D ↗
2026-04-29 Zachary Jennifer Officer M-Exempt D Restricted Stock Unit 2,951 0.00 — 5,903 D ↗
2026-04-29 Williams David Michael Officer M-Exempt A Common Stock 1,377 110.03 151.5K 32,395 D ↗
2026-04-29 Smart Dalton E. III Officer M-Exempt A Common Stock 944 110.03 103.9K 9,156 D ↗
2026-04-29 Oosthuizen Johannes Jacobus Officer M-Exempt A Common Stock 1,377 110.03 151.5K 22,574 D ↗
2026-04-29 Litchfield Caroline Officer M-Exempt A Common Stock 3,935 110.03 433.0K 94,239 D ↗
2026-04-29 Li Dean Y Officer M-Exempt D Restricted Stock Unit 4,722 0.00 — 9,444 D ↗
2026-04-29 Larson Betty D Officer F-InKind D Common Stock 715 110.03 78.7K 7,567 D ↗
2026-04-29 Guindo Chirfi Officer M-Exempt A Common Stock 1,967 110.03 216.4K 62,582 D ↗
2026-04-29 DeLuca Richard R. Officer M-Exempt D Restricted Stock Unit 2,518 0.00 — 5,037 D ↗
2026-04-29 Davis Robert M Director / Officer M-Exempt A Common Stock 13,300 110.03 1.46M 456,902 D ↗
2026-04-29 Chattopadhyay Sanat Officer M-Exempt A Common Stock 2,597 110.03 285.7K 16,477 D ↗
2026-03-31 Seidman Christine E Director A-Award A Phantom Stock 68 0.00 — 19,238 D ↗
2026-03-31 GLOCER THOMAS H Director A-Award A Phantom Stock 405 0.00 — 108,293 D ↗
2026-03-31 Coe Mary Ellen Director A-Award A Phantom Stock 249 0.00 — 29,703 D ↗
2026-03-02 Foard Brian Officer — — — 0 0.00 — 0 — ↗
2026-02-12 Guindo Chirfi Officer S-Sale D Common Stock 10,000 121.46 1.21M 60,615 D ↗
2026-02-10 Li Dean Y Officer S-Sale D Common Stock 10,235 117.52 1.20M 92,035 D ↗
2026-02-09 Zachary Jennifer Officer M-Exempt D Stock Option (Right to Buy) 25,946 75.36 1.96M 0 D ↗
2026-02-09 Guindo Chirfi Officer S-Sale D Common Stock 10,000 118.41 1.18M 70,615 D ↗
2026-02-06 Williams David Michael Officer M-Exempt A Common Stock 5,000 77.62 388.1K 35,838 D ↗
2026-02-06 Oosthuizen Johannes Jacobus Officer S-Sale D Common Stock 15,000 121.87 1.83M 21,197 D ↗
2026-02-06 DeLuca Richard R. Officer S-Sale D Common Stock 37,685 120.92 4.56M 160,174 D ↗
2026-02-05 Guindo Chirfi Officer S-Sale D Common Stock 20,000 121.88 2.44M 80,615 D ↗
2026-02-04 Smart Dalton E. III Officer S-Sale D Common Stock 2,400 119.68 287.2K 8,205 D ↗
2026-02-04 Litchfield Caroline Officer M-Exempt D Stock Option (Right to Buy) 41,997 53.06 2.23M 0 D ↗
2026-02-04 Li Dean Y Officer M-Exempt D Stock Option (Right to Buy) 15,087 56.04 845.5K 0 D ↗
2026-02-04 Davis Robert M Director / Officer S-Sale D Common Stock 14,972 117.38 1.76M 476,064 D ↗
2026-01-26 Zachary Jennifer Officer A-Award A Common Stock 11,583 107.40 1.24M 68,916 D ↗
2026-01-26 Williams David Michael Officer A-Award A Common Stock 6,112 107.40 656.4K 30,838 D ↗
2026-01-26 Smart Dalton E. III Officer A-Award A Common Stock 1,066 107.40 114.5K 10,605 D ↗
2026-01-26 Romanelli Joseph Officer A-Award A Common Stock 5,703 107.40 612.5K 28,739 D ↗
2026-01-26 Oosthuizen Johannes Jacobus Officer A-Award A Common Stock 5,026 107.40 539.8K 36,197 D ↗
2026-01-26 Litchfield Caroline Officer A-Award A Common Stock 15,852 107.40 1.70M 90,192 D ↗
2026-01-26 Li Dean Y Officer A-Award A Common Stock 20,469 107.40 2.20M 102,270 D ↗
2026-01-26 Guindo Chirfi Officer A-Award A Common Stock 9,865 107.40 1.06M 100,615 D ↗
2026-01-26 DeLuca Richard R. Officer A-Award A Common Stock 12,264 107.40 1.32M 197,859 D ↗
2026-01-26 Davis Robert M Director / Officer A-Award A Common Stock 47,434 107.40 5.09M 491,036 D ↗
2026-01-26 Chattopadhyay Sanat Officer A-Award A Common Stock 13,880 107.40 1.49M 13,880 D ↗
2025-12-31 Seidman Christine E Director A-Award A Phantom Stock 77 0.00 — 19,026 D ↗
2025-12-31 GLOCER THOMAS H Director A-Award A Phantom Stock 463 0.00 — 107,076 D ↗
2025-12-31 Coe Mary Ellen Director A-Award A Phantom Stock 285 0.00 — 29,232 D ↗
2025-11-10 Downing Cristal N Officer S-Sale D Common Stock 7,085 87.00 616.4K 0 D ↗
2025-11-03 Williams David Michael Officer S-Sale D Common Stock 8,614 83.59 720.0K 24,578 D ↗
2025-09-30 Seidman Christine E Director A-Award A Phantom Stock 97 0.00 — 18,776 D ↗
2025-09-30 GLOCER THOMAS H Director A-Award A Phantom Stock 581 0.00 — 105,646 D ↗
2025-09-30 Coe Mary Ellen Director A-Award A Phantom Stock 357 0.00 — 28,685 D ↗
2025-08-04 Williams David Michael Officer F-InKind D Common Stock 8,432 79.29 668.6K 33,013 D ↗
2025-08-04 Guindo Chirfi Officer M-Exempt A Common Stock 36,903 79.29 2.93M 107,409 D ↗
2025-06-30 Seidman Christine E Director A-Award A Phantom Stock 103 0.00 — 18,496 D ↗
2025-06-30 GLOCER THOMAS H Director A-Award A Phantom Stock 616 0.00 — 104,041 D ↗
2025-06-30 Coe Mary Ellen Director A-Award A Phantom Stock 379 0.00 — 28,052 D ↗
2025-05-30 Warden Kathy J Director A-Award A Phantom Stock 2,863 0.00 — 15,504 D ↗
2025-05-30 THULIN INGE G Director A-Award A Phantom Stock 2,863 0.00 — 24,764 D ↗
2025-05-30 Seidman Christine E Director A-Award A Phantom Stock 2,863 0.00 — 18,393 D ↗
2025-05-30 Rothman Paul Director A-Award A Phantom Stock 2,863 0.00 — 31,991 D ↗
2025-05-30 RUSSO PATRICIA F Director A-Award A Phantom Stock 2,863 0.00 — 58,523 D ↗
2025-05-30 Mayo Stephen Director A-Award A Phantom Stock 2,863 0.00 — 12,540 D ↗
2025-05-30 LAVIZZO-MOUREY RISA J Director A-Award A Phantom Stock 2,863 0.00 — 15,367 D ↗
2025-05-30 Karsanbhai Surendralal Lanca Director A-Award A Phantom Stock 2,863 0.00 — 3,421 D ↗
2025-05-30 GLOCER THOMAS H Director A-Award A Phantom Stock 2,863 0.00 — 103,425 D ↗
2025-05-30 Craig Pamela J. Director A-Award A Phantom Stock 2,863 0.00 — 31,991 D ↗
2025-05-30 Coe Mary Ellen Director A-Award A Phantom Stock 2,863 0.00 — 27,673 D ↗
2025-05-30 BAKER DOUGLAS M JR Director A-Award A Phantom Stock 2,863 0.00 — 9,344 D ↗
2025-05-03 Smart Dalton E. III Officer M-Exempt A Common Stock 1,532 83.18 127.4K 10,127 D ↗
2025-05-02 Smart Dalton E. III Officer M-Exempt D Restricted Stock Unit 381 0.00 — 383 D ↗
2025-05-02 Romanelli Joseph Officer F-InKind D Common Stock 1,115 83.26 92.8K 22,946 D ↗
2025-04-30 Smart Dalton E. III Officer F-InKind D Common Stock 159 84.71 13.5K 8,083 D ↗
2025-04-30 Romanelli Joseph Officer M-Exempt D Restricted Stock Unit 2,063 0.00 — 4,128 D ↗
2025-04-30 Larson Betty D Officer F-InKind D Common Stock 5,153 84.71 436.5K 6,197 D ↗
2025-04-29 Zachary Jennifer Officer A-Award A Stock Option (Right to Buy) 40,301 84.71 3.41M 40,301 D ↗
2025-04-29 Williams David Michael Officer A-Award A Stock Option (Right to Buy) 18,807 84.71 1.59M 18,807 D ↗
2025-04-29 Smart Dalton E. III Officer A-Award A Stock Option (Right to Buy) 6,448 84.71 546.2K 6,448 D ↗
2025-04-29 Romanelli Joseph Officer A-Award A Restricted Stock Unit 9,444 0.00 — 9,444 D ↗
2025-04-29 Oosthuizen Johannes Jacobus Officer A-Award A Stock Option (Right to Buy) 18,807 84.71 1.59M 18,807 D ↗
2025-04-29 Litchfield Caroline Officer A-Award A Restricted Stock Unit 11,805 0.00 — 11,805 D ↗
2025-04-29 Li Dean Y Officer A-Award A Restricted Stock Unit 14,166 0.00 — 14,166 D ↗
2025-04-29 Larson Betty D Officer A-Award A Stock Option (Right to Buy) 28,479 84.71 2.41M 28,479 D ↗
2025-04-29 Guindo Chirfi Officer A-Award A Stock Option (Right to Buy) 26,867 84.71 2.28M 26,867 D ↗
2025-04-29 Downing Cristal N Officer A-Award A Stock Option (Right to Buy) 13,971 84.71 1.18M 13,971 D ↗
2025-04-29 DeLuca Richard R. Officer A-Award A Stock Option (Right to Buy) 34,390 84.71 2.91M 34,390 D ↗
2025-04-29 Davis Robert M Director / Officer A-Award A Restricted Stock Unit 39,901 0.00 — 39,901 D ↗
2025-04-29 Chattopadhyay Sanat Officer A-Award A Stock Option (Right to Buy) 35,465 84.71 3.00M 35,465 D ↗
2025-04-25 Smart Dalton E. III Officer M-Exempt A Common Stock 5,000 58.08 290.4K 12,040 D ↗
2025-03-31 Seidman Christine E Director A-Award A Phantom Stock 91 0.00 — 15,378 D ↗
2025-03-31 GLOCER THOMAS H Director A-Award A Phantom Stock 543 0.00 — 99,579 D ↗
2025-03-31 Coe Mary Ellen Director A-Award A Phantom Stock 334 0.00 — 24,568 D ↗
2025-02-19 Oosthuizen Johannes Jacobus Officer S-Sale D Common Stock 8,500 84.09 714.7K 30,705 D ↗
2025-02-13 Williams David Michael Officer S-Sale D Common Stock 6,000 85.34 512.1K 24,123 D ↗
2025-02-08 Oosthuizen Johannes Jacobus Officer M-Exempt A Common Stock 13,002 87.28 1.13M 45,609 D ↗
2025-02-06 THULIN INGE G Director P-Purchase A Common Stock 2,833 88.25 250.0K 2,933 D ↗
2025-02-06 Downing Cristal N Officer S-Sale D Common Stock 2,361 88.76 209.6K 7,085 D ↗
2025-02-05 BAKER DOUGLAS M JR Director P-Purchase A Common Stock 15,000 88.50 1.33M 16,000 D ↗
2025-01-27 Zachary Jennifer Officer A-Award A Common Stock 25,423 97.94 2.49M 55,286 D ↗
2025-01-27 Williams David Michael Officer A-Award A Common Stock 10,246 97.94 1.00M 30,123 D ↗
2025-01-27 Smart Dalton Officer A-Award A Common Stock 2,586 97.94 253.3K 7,014 D ↗
2025-01-27 Oosthuizen Johannes Jacobus Officer A-Award A Common Stock 8,664 97.94 848.6K 32,607 D ↗
2025-01-27 Litchfield Caroline Officer A-Award A Common Stock 23,432 97.94 2.29M 74,340 D ↗
2025-01-27 Li Dean Y Officer A-Award A Common Stock 32,621 97.94 3.19M 79,592 D ↗
2025-01-27 Guindo Chirfi Officer A-Award A Common Stock 28,158 97.94 2.76M 69,144 D ↗
2025-01-27 Downing Cristal N Officer A-Award A Common Stock 9,446 97.94 925.1K 9,446 D ↗
2025-01-27 DeLuca Richard R. Officer A-Award A Common Stock 25,438 97.94 2.49M 178,993 D ↗
2025-01-27 Davis Robert M Director / Officer A-Award A Common Stock 95,275 97.94 9.33M 443,602 D ↗
2025-01-27 Chattopadhyay Sanat Officer A-Award A Common Stock 28,136 97.94 2.76M 78,758 D ↗
2025-01-01 Karsanbhai Surendralal Lanca Director — — Common Stock 0 0.00 — 1 D ↗
2024-12-31 Seidman Christine E Director A-Award A Phantom Stock 82 0.00 — 15,165 D ↗
2024-12-31 GLOCER THOMAS H Director A-Award A Phantom Stock 490 0.00 — 98,247 D ↗
2024-12-31 Coe Mary Ellen Director A-Award A Phantom Stock 302 0.00 — 24,041 D ↗
2024-09-30 Seidman Christine E Director A-Award A Phantom Stock 72 0.00 — 14,977 D ↗
2024-09-30 GLOCER THOMAS H Director A-Award A Phantom Stock 429 0.00 — 97,075 D ↗
2024-09-30 Coe Mary Ellen Director A-Award A Phantom Stock 264 0.00 — 23,574 D ↗
2024-08-05 Guindo Chirfi Officer F-InKind D Common Stock 17,412 115.20 2.01M 40,370 — ↗
2024-06-28 Seidman Christine E Director A-Award A Phantom Stock 66 0.00 — 14,816 — ↗
2024-06-28 GLOCER THOMAS H Director A-Award A Phantom Stock 394 0.00 — 96,063 — ↗
2024-06-28 Coe Mary Ellen Director A-Award A Phantom Stock 242 0.00 — 23,170 — ↗
2024-05-31 Warden Kathy J Director A-Award A Phantom Stock 1,752 0.00 — 12,252 — ↗
2024-05-31 THULIN INGE G Director A-Award A Phantom Stock 1,752 0.00 — 21,229 — ↗
2024-05-31 Seidman Christine E Director A-Award A Phantom Stock 1,752 0.00 — 14,750 — ↗
2024-05-31 Rothman Paul Director A-Award A Phantom Stock 1,752 0.00 — 28,234 — ↗
2024-05-31 RUSSO PATRICIA F Director A-Award A Phantom Stock 1,752 0.00 — 53,952 — ↗
2024-05-31 Mayo Stephen Director A-Award A Phantom Stock 1,752 0.00 — 9,380 — ↗
2024-05-31 LAVIZZO-MOUREY RISA J Director A-Award A Phantom Stock 1,752 0.00 — 12,120 — ↗
2024-05-31 GLOCER THOMAS H Director A-Award A Phantom Stock 1,752 0.00 — 95,669 — ↗
2024-05-31 Craig Pamela J. Director A-Award A Phantom Stock 1,752 0.00 — 28,234 — ↗
2024-05-31 Coe Mary Ellen Director A-Award A Phantom Stock 1,752 0.00 — 22,927 — ↗
2024-05-31 BAKER DOUGLAS M JR Director A-Award A Phantom Stock 1,752 0.00 — 6,282 — ↗
2024-05-04 Smart Dalton Officer — D Restricted Stock Unit 612 0.00 — 0 — ↗
2024-05-04 Oosthuizen Johannes Jacobus Officer M-Exempt D Restricted Stock Unit 912 0.00 — 0 — ↗
2024-05-04 Klobuchar Michael A Officer M-Exempt D Restricted Stock Unit 887 0.00 — 0 — ↗
2024-05-04 DeLuca Richard R. Officer M-Exempt A Common Stock 27,126 127.51 3.46M 163,720 — ↗
2024-05-03 Smart Dalton Officer M-Exempt D Restricted Stock Unit 1,530 0.00 — 1,532 — ↗
2024-05-02 Smart Dalton Officer M-Exempt D Restricted Stock Unit 381 0.00 — 764 — ↗
2024-05-02 Romanelli Joseph Officer M-Exempt D Restricted Stock Unit 2,262 0.00 — 4,524 — ↗
2024-04-30 Zachary Jennifer Officer A-Award A Stock Option (Right to Buy) 35,156 129.22 4.54M 35,156 — ↗
2024-04-30 Williams David Michael Officer A-Award A Stock Option (Right to Buy) 16,406 129.22 2.12M 16,406 — ↗
2024-04-30 Smart Dalton Officer A-Award A Restricted Stock Unit 1,393 0.00 — 1,393 — ↗
2024-04-30 Romanelli Joseph Officer A-Award A Restricted Stock Unit 6,191 0.00 — 6,191 — ↗
2024-04-30 Oosthuizen Johannes Jacobus Officer A-Award A Stock Option (Right to Buy) 20,508 129.22 2.65M 20,508 — ↗
2024-04-30 Litchfield Caroline Officer A-Award A Stock Option (Right to Buy) 49,805 129.22 6.44M 49,805 — ↗
2024-04-30 Li Dean Y Officer A-Award A Stock Option (Right to Buy) 65,625 129.22 8.48M 65,625 — ↗
2024-04-30 Larson Betty D Officer A-Award A Stock Option (Right to Buy) 58,594 129.22 7.57M 58,594 — ↗
2024-04-30 Klobuchar Michael A Officer A-Award A Stock Option (Right to Buy) 20,508 129.22 2.65M 20,508 — ↗
2024-04-30 Guindo Chirfi Officer A-Award A Stock Option (Right to Buy) 29,297 129.22 3.79M 29,297 — ↗
2024-04-30 Downing Cristal N Officer A-Award A Stock Option (Right to Buy) 15,234 129.22 1.97M 15,234 — ↗
2024-04-30 DeLuca Richard R. Officer A-Award A Restricted Stock Unit 23,216 0.00 — 23,216 — ↗
2024-04-30 Davis Robert M Director / Officer A-Award A Stock Option (Right to Buy) 181,641 129.22 23.47M 181,641 — ↗
2024-04-30 Chattopadhyay Sanat Officer A-Award A Stock Option (Right to Buy) 38,672 129.22 5.00M 38,672 — ↗
2024-04-01 Larson Betty D Officer — — — 0 0.00 — 0 — ↗
2024-03-28 WENDELL PETER C Director A-Award A Phantom Stock 227 0.00 — 124,753 — ↗
2024-03-28 Seidman Christine E Director A-Award A Phantom Stock 62 0.00 — 12,920 — ↗
2024-03-28 GLOCER THOMAS H Director A-Award A Phantom Stock 341 0.00 — 93,360 — ↗
2024-03-28 Coe Mary Ellen Director A-Award A Phantom Stock 227 0.00 — 21,050 — ↗
2024-02-14 Litchfield Caroline Officer S-Sale D Common Stock 38,291 125.50 4.81M 50,908 — ↗
2024-02-14 Davis Robert M Director / Officer M-Exempt A Common Stock 85,021 73.73 6.27M 433,348 — ↗
2024-02-13 Romanelli Joseph Officer S-Sale D Common Stock 1,000 124.89 124.9K 19,569 — ↗
2024-02-13 Davis Robert M Director / Officer M-Exempt D Stock Option (Right to Buy) 108,491 73.73 8.00M 181,781 — ↗
2024-02-09 Li Dean Y Officer M-Exempt A Common Stock 14,702 62.07 912.6K 60,944 — ↗
2024-02-07 Williams David Michael Officer S-Sale D Common Stock 1,451 127.57 185.1K 19,812 — ↗
2024-02-02 Zachary Jennifer Officer S-Sale D Common Stock 49,499 126.97 6.28M 29,058 — ↗
2024-02-02 Oosthuizen Johannes Jacobus Officer M-Exempt A Common Stock 7,045 73.73 519.4K 35,167 — ↗
2024-02-02 MIZELL STEVEN Officer M-Exempt A Common Stock 824 70.71 58.3K 42,143 — ↗
2024-01-22 Zachary Jennifer Officer A-Award A Common Stock 23,298 119.43 2.78M 59,140 — ↗
2024-01-22 Williams David Michael Officer A-Award A Common Stock 10,196 119.43 1.22M 21,263 — ↗
2024-01-22 Smart Dalton Officer A-Award A Common Stock 2,661 119.43 317.8K 2,667 — ↗
2024-01-22 Oosthuizen Johannes Jacobus Officer A-Award A Common Stock 3,133 119.43 374.2K 21,349 — ↗
2024-01-22 MIZELL STEVEN Officer A-Award A Common Stock 18,384 119.43 2.20M 41,319 — ↗
2024-01-22 Litchfield Caroline Officer A-Award A Common Stock 19,208 119.43 2.29M 50,908 — ↗
2024-01-22 Li Dean Y Officer A-Award A Common Stock 25,760 119.43 3.08M 46,242 — ↗
2024-01-22 Klobuchar Michael A Officer A-Award A Common Stock 3,896 119.43 465.3K 23,098 — ↗
2024-01-22 DeLuca Richard R. Officer A-Award A Common Stock 23,296 119.43 2.78M 135,783 — ↗
2024-01-22 Davis Robert M Director / Officer A-Award A Common Stock 76,510 119.43 9.14M 348,327 — ↗
2024-01-22 Chattopadhyay Sanat Officer A-Award A Common Stock 26,716 119.43 3.19M 26,716 — ↗
2023-12-29 WENDELL PETER C Director A-Award A Phantom Stock 275 0.00 — 123,716 — ↗
2023-12-29 Seidman Christine E Director A-Award A Phantom Stock 75 0.00 — 12,775 — ↗
2023-12-29 GLOCER THOMAS H Director A-Award A Phantom Stock 413 0.00 — 92,419 — ↗
2023-12-29 Coe Mary Ellen Director A-Award A Phantom Stock 275 0.00 — 20,688 — ↗
2023-12-04 Smart Dalton Officer — D Common Stock 0 0.00 — 6 — ↗
2023-11-09 Oosthuizen Johannes Jacobus Officer S-Sale D Common Stock 2,081 102.38 213.1K 18,191 — ↗
2023-11-08 DeLuca Richard R. Officer S-Sale D Common Stock 43,823 105.03 4.60M 111,764 — ↗
2023-10-31 Downing Cristal N Officer A-Award A Restricted Stock Unit 11,685 0.00 — 11,685 — ↗
2023-10-30 Oosthuizen Johannes Jacobus Officer F-InKind D Common Stock 451 102.82 46.4K 20,272 — ↗
2023-09-29 WENDELL PETER C Director A-Award A Phantom Stock 291 0.00 — 122,581 — ↗
2023-09-29 Seidman Christine E Director A-Award A Phantom Stock 79 0.00 — 12,613 — ↗
2023-09-29 GLOCER THOMAS H Director A-Award A Phantom Stock 437 0.00 — 91,371 — ↗
2023-09-29 Coe Mary Ellen Director A-Award A Phantom Stock 291 0.00 — 20,273 — ↗
2023-08-14 MIZELL STEVEN Officer S-Sale D Common Stock 4,250 109.01 463.3K 22,935 — ↗
2023-08-03 MIZELL STEVEN Officer S-Sale D Common Stock 4,500 105.49 474.7K 27,185 — ↗
2023-08-03 Guindo Chirfi Officer M-Exempt D Restricted Stock Unit 36,901 0.00 — 73,804 — ↗
2023-08-02 Romanelli Joseph Officer S-Sale D Common Stock 59 107.37 6.3K 0 — ↗
2023-06-30 WENDELL PETER C Director A-Award A Phantom Stock 260 0.00 — 121,485 — ↗
2023-06-30 Seidman Christine E Director A-Award A Phantom Stock 70 0.00 — 12,451 — ↗
2023-06-30 GLOCER THOMAS H Director A-Award A Phantom Stock 390 0.00 — 90,340 — ↗
2023-06-30 Coe Mary Ellen Director A-Award A Phantom Stock 260 0.00 — 19,851 — ↗
2023-05-26 Warden Kathy J Director A-Award A Phantom Stock 1,981 0.00 — 10,229 — ↗
2023-05-26 WENDELL PETER C Director A-Award A Phantom Stock 1,981 0.00 — 121,225 — ↗
2023-05-26 THULIN INGE G Director A-Award A Phantom Stock 1,981 0.00 — 18,974 — ↗
2023-05-26 Seidman Christine E Director A-Award A Phantom Stock 1,981 0.00 — 12,381 — ↗
2023-05-26 Rothman Paul Director A-Award A Phantom Stock 1,981 0.00 — 25,798 — ↗
2023-05-26 RUSSO PATRICIA F Director A-Award A Phantom Stock 1,981 0.00 — 50,852 — ↗

Executive team

Top executives
EBIT / Employee
321.7K
Shares Outstanding
2.47B

Executive compensation

Executive compensation (annual)
# Year ⇅ Executive ⇅ Salary ⇅ Bonus Stock award ⇅ Option award Incentive Other Total ⇅ % Stock-
based ⇅		 Filing
1 2025 Robert M. Davis Chairman, Chief Executive Officer and President 1.65M — 12.10M 3.38M 2.33M 1.34M 20.80M 74.44% ↗
2 2025 Dean Li, M.D., Ph.D. Executive Vice President and President, Merck Research Laboratories 1.46M — 4.30M 1.20M 1.37M 567.4K 8.89M 61.81% ↗
3 2025 Caroline Litchfield Executive Vice President and Chief Financial Officer 1.17M — 3.58M 1.00M 1.10M 660.4K 7.51M 60.96% ↗
4 2025 Jennifer Zachary Executive Vice President and General Counsel 1.06M — 2.69M 750.0K 995.7K 367.0K 5.86M 58.62% ↗
5 2025 Sanat Chattopadhyay Executive Vice President and President, Merck Manufacturing Division 982.2K — 2.36M 660.0K 920.7K 482.3K 5.41M 55.90% ↗
6 2024 Robert M. Davis Chairman, Chief Executive Officer and President 1.62M — 13.08M 4.65M 2.76M 1.07M 23.19M 76.46% ↗
7 2024 Betty Larson Executive Vice President and Chief Human Resources Officer 604.4K 725.0K 6.64M 2.30M 685.2K 312.4K 11.26M 79.33% ↗
8 2024 Dean Li, M.D., Ph.D. Executive Vice President and President, Merck Research Laboratories 1.45M — 4.72M 1.68M 1.66M 570.7K 10.09M 63.50% ↗
9 2024 Richard R. DeLuca, Jr. Executive Vice President and President, Merck Animal Health 958.7K — 5.70M 960.0K 1.10M 383.3K 9.10M 73.20% ↗
10 2024 Caroline Litchfield Executive Vice President and Chief Financial Officer 1.17M — 3.59M 1.28M 1.33M 147.2K 7.51M 64.74% ↗
11 2024 Sanat Chattopadhyay Executive Vice President and President, Merck Manufacturing Division 976.2K — 2.78M 990.0K 1.12M 296.1K 6.16M 61.24% ↗
12 2023 Robert M. Davis Chairman, Chief Executive Officer and President 1.60M — 10.00M 4.05M 3.59M 1.04M 20.27M 69.29% ↗
13 2023 Dean Li, M.D., Ph.D. Executive Vice President and President, Merck Research Laboratories 1.37M — 4.15M 1.68M 2.07M 511.4K 9.78M 59.59% ↗
14 2023 Caroline Litchfield Executive Vice President and Chief Financial Officer 1.09M — 3.15M 1.28M 1.67M 1.12M 8.30M 53.28% ↗
15 2023 Sanat Chattopadhyay Executive Vice President and President, Merck Manufacturing Division 934.9K — 2.44M 990.0K 1.39M 477.7K 6.24M 55.03% ↗
16 2023 Richard R. DeLuca, Jr. Executive Vice President and President, Merck Animal Health 910.0K — 2.37M 960.0K 1.37M 589.0K 6.20M 53.73% ↗
17 2022 Robert M. Davis Chairman, Chief Executive Officer and President 1.54M — 8.87M 3.52M 4.13M 592.7K 18.65M 66.45% ↗
18 2022 Chirfi Guindo Chief Marketing Officer, Human Health 348.1K 530.0K 12.40M — 502.5K 161.1K 13.94M 88.94% ↗
19 2022 Kenneth C. Frazier Former Executive Chairman 1.15M — 5.00M — 2.04M 323.5K 8.51M 58.75% ↗
20 2022 Dean Li, M.D., Ph.D. Executive Vice President and President, Merck Research Laboratories 1.10M — 2.94M 1.17M 2.23M 332.4K 7.77M 52.97% ↗
21 2022 Caroline Litchfield Executive Vice President and Chief Financial Officer 960.0K — 2.08M 825.0K 1.74M 326.6K 5.92M 48.97% ↗
22 2022 Jennifer Zachary Executive Vice President and General Counsel 970.7K — 2.26M 900.0K 1.65M 113.4K 5.90M 53.66% ↗
23 2022 Richard R. DeLuca, Jr. Executive Vice President and President, Merck Animal Health 840.5K — 2.26M 900.0K 1.51M 101.0K 5.62M 56.32% ↗
24 2021 Kenneth C. Frazier Executive Chairman and Former Chief Executive Officer 1.48M — 7.39M 3.23M 2.80M 299.0K 15.20M 69.85% ↗
25 2021 Kenneth C. Frazier Former Executive Chairman 1.48M — 7.39M 3.23M 2.80M 299.0K 15.20M 69.85% ↗
26 2021 Robert M. Davis Chief Executive Officer, President and Former Chief Financial Officer 1.32M — 6.32M 2.76M 2.83M 483.0K 13.72M 66.20% ↗
27 2021 Robert M. Davis Chairman, Chief Executive Officer and President 1.32M — 6.32M 2.76M 2.83M 483.0K 13.72M 66.20% ↗
28 2021 Frank Clyburn Former Executive Vice President and President, Human Health 960.3K — 5.96M 1.29M 1.44M 271.2K 9.92M 73.04% ↗
29 2021 Richard R. DeLuca, Jr. Executive Vice President and President, Merck Animal Health 790.2K — 3.86M 810.0K 1.18M 200.6K 6.84M 68.21% ↗
30 2021 Dean Li, M.D., Ph.D. Executive Vice President and President, Merck Research Laboratories 937.1K — 2.06M 900.0K 1.40M 180.7K 5.48M 54.05% ↗
31 2021 Jennifer Zachary Executive Vice President and General Counsel 942.3K — 1.86M 810.0K 1.33M 246.8K 5.19M 51.41% ↗
32 2021 Caroline Litchfield Executive Vice President and Chief Financial Officer 805.1K — 1.51M 660.0K 1.18M 434.9K 4.60M 47.26% ↗
33 2020 Kenneth C. Frazier Executive Chairman and Former Chief Executive Officer 1.70M — 10.78M 4.72M 2.22M 2.67M 22.09M 70.18% ↗
34 2020 Kenneth C. Frazier Former Executive Chairman 1.70M — 10.78M 4.72M 2.22M 2.67M 22.09M 70.18% ↗
35 2020 Kenneth C. Frazier Chairman and Chief Executive Officer 1.70M — 10.78M 4.72M 2.22M 2.67M 22.09M 70.18% ↗
36 2020 Roger M. Perlmutter, M.D., Ph.D. Former Executive Vice President and President, Merck Research Laboratories 1.19M — 3.42M 1.50M 1.09M 620.6K 7.82M 62.90% ↗
37 2020 Robert M. Davis Chairman, Chief Executive Officer and President 1.11M — 2.74M 1.20M 1.02M 771.3K 6.84M 57.57% ↗
38 2020 Robert M. Davis President and Former Chief Financial Officer 1.11M — 2.74M 1.20M 1.02M 771.3K 6.84M 57.57% ↗
39 2020 Robert M. Davis Chief Executive Officer, President and Former Chief Financial Officer 1.11M — 2.74M 1.20M 1.02M 771.3K 6.84M 57.57% ↗
40 2020 Sanat Chattopadhyay Executive Vice President and President, Merck Manufacturing Division 805.0K — 1.92M 839.8K 646.0K 739.1K 4.95M 55.72% ↗
41 2020 Jennifer Zachary Executive Vice President and General Counsel 913.1K — 1.71M 749.9K 759.3K 424.0K 4.56M 54.00% ↗
42 2020 Jennifer Zachary Executive Vice President, General Counsel and Corporate Secretary 913.1K — 1.71M 749.9K 759.3K 424.0K 4.56M 54.00% ↗
43 2019 Kenneth C. Frazier Chairman and Chief Executive Officer 1.66M — 11.43M 4.50M 4.61M 5.45M 27.65M 57.60% ↗
44 2019 Kenneth C. Frazier Chairman, President and Chief Executive Officer 1.66M — 11.43M 4.50M 4.61M 5.45M 27.65M 57.60% ↗
45 2019 Kenneth C. Frazier Executive Chairman and Former Chief Executive Officer 1.66M — 11.43M 4.50M 4.61M 5.45M 27.65M 57.60% ↗
46 2019 Roger M. Perlmutter, M.D., Ph.D. Executive Vice President and President, Merck Research Laboratories 1.15M — 3.81M 1.50M 2.24M 524.0K 9.22M 57.56% ↗
47 2019 Roger M. Perlmutter, M.D., Ph.D. Former Executive Vice President and President, Merck Research Laboratories 1.15M — 3.81M 1.50M 2.24M 524.0K 9.22M 57.56% ↗
48 2019 Robert M. Davis Chief Executive Officer, President and Former Chief Financial Officer 1.08M — 3.05M 1.20M 2.09M 313.9K 7.73M 54.96% ↗
49 2019 Robert M. Davis President and Former Chief Financial Officer 1.08M — 3.05M 1.20M 2.09M 313.9K 7.73M 54.96% ↗
50 2019 Robert M. Davis Executive Vice President, Global Services and Chief Financial Officer 1.08M — 3.05M 1.20M 2.09M 313.9K 7.73M 54.96% ↗
51 2019 Sanat Chattopadhyay Executive Vice President and President, Merck Manufacturing Division 719.5K — 1.75M 690.1K 1.20M 1.06M 5.42M 45.07% ↗
52 2019 Jennifer Zachary Executive Vice President, General Counsel and Corporate Secretary 856.8K — 1.79M 705.1K 1.53M 164.3K 5.05M 49.45% ↗
53 2018 Kenneth C. Frazier Chairman and Chief Executive Officer 1.61M — 9.46M 3.90M 3.06M 2.91M 20.93M 63.80% ↗
54 2018 Kenneth C. Frazier Chairman, President and Chief Executive Officer 1.61M — 9.46M 3.90M 3.06M 2.91M 20.93M 63.80% ↗
55 2018 Roger M. Perlmutter, M.D., Ph.D. Executive Vice President and President, Merck Research Laboratories 1.12M — 2.91M 1.20M 1.49M 384.0K 7.10M 57.90% ↗
56 2018 Roger M. Perlmutter, M.D., Ph.D. Former Executive Vice President and President, Merck Research Laboratories 1.12M — 2.91M 1.20M 1.49M 384.0K 7.10M 57.90% ↗
57 2018 Robert M. Davis Executive Vice President, Global Services, and Chief Financial Officer 1.04M — 2.76M 1.14M 1.39M 282.8K 6.62M 58.97% ↗
58 2018 Robert M. Davis President and Former Chief Financial Officer 1.04M — 2.76M 1.14M 1.39M 282.8K 6.62M 58.97% ↗
59 2018 Robert M. Davis Executive Vice President, Global Services and Chief Financial Officer 1.04M — 2.76M 1.14M 1.39M 282.8K 6.62M 58.97% ↗
60 2018 Adam H. Schechter Former Executive Vice President and President, Global Human Health 1.06M — 2.76M 1.14M 1.41M 140.2K 6.51M 60.02% ↗
61 2018 Jennifer L. Zachary Executive Vice President and General Counsel 553.8K 750.0K 2.45M 600.2K 638.4K 196.5K 5.19M 58.82% ↗
62 2018 Jennifer Zachary Executive Vice President, General Counsel and Corporate Secretary 553.8K 750.0K 2.45M 600.2K 638.4K 196.5K 5.19M 58.82% ↗
63 2017 Kenneth C. Frazier, Chairman, President and Chief Executive Officer 1.57M — 8.81M 3.75M 2.69M 819.5K 17.64M 71.22% ↗
64 2017 Kenneth C. Frazier Chairman, President and Chief Executive Officer 1.57M — 8.81M 3.75M 2.69M 819.5K 17.64M 71.22% ↗
65 2017 Adam H. Schechter, Executive Vice President and President, Global Human Health 1.03M — 2.68M 1.14M 1.23M 1.77M 7.85M 48.66% ↗
66 2017 Adam H. Schechter Former Executive Vice President and President, Global Human Health 1.03M — 2.68M 1.14M 1.23M 1.77M 7.85M 48.66% ↗
67 2017 Roger M. Perlmutter, M.D., Ph.D. Executive Vice President and President, Merck Research Laboratories 1.08M — 2.82M 1.20M 1.30M 433.4K 6.83M 58.84% ↗
68 2017 Roger M. Perlmutter, M.D., Ph.D., Executive Vice President and President, Merck Research Laboratories 1.08M — 2.82M 1.20M 1.30M 423.4K 6.82M 58.92% ↗
69 2017 Robert M. Davis Executive Vice President, Global Services and Chief Financial Officer 1.02M — 2.68M 1.14M 1.22M 256.8K 6.31M 60.52% ↗
70 2017 Robert M. Davis Executive Vice President, Global Services, and Chief Financial Officer 1.02M — 2.68M 1.14M 1.22M 256.8K 6.31M 60.52% ↗
71 2017 Robert M. Davis, Executive Vice President, Global Services, and Chief Financial Officer 1.02M — 2.68M 1.14M 1.22M 256.8K 6.31M 60.52% ↗
72 2017 Michael J. Holston , Executive Vice President and General Counsel 811.5K — 1.55M 660.0K 885.6K 536.7K 4.45M 49.75% ↗
73 2016 Kenneth C. Frazier, Chairman, President and Chief Executive Officer 1.53M — 7.88M 4.80M 2.52M 5.06M 21.78M 58.19% ↗
74 2016 Kenneth C. Frazier Chairman, President and Chief Executive Officer 1.53M — 7.88M 4.80M 2.52M 5.06M 21.78M 58.19% ↗
75 2016 Adam H. Schechter, Executive Vice President and President, Global Human Health 1.00M — 2.49M 1.52M 1.10M 2.15M 8.27M 48.52% ↗
76 2016 Adam H. Schechter Former Executive Vice President and President, Global Human Health 1.00M — 2.49M 1.52M 1.10M 2.15M 8.27M 48.52% ↗
77 2016 Robert M. Davis, Executive Vice President, Global Services and Chief Financial Officer 991.7K 1.25M 2.43M 1.48M 1.09M 277.5K 7.52M 51.98% ↗
78 2016 Robert M. Davis, Executive Vice President, Global Services, and Chief Financial Officer 991.7K 1.25M 2.43M 1.48M 1.09M 277.5K 7.52M 51.98% ↗
79 2016 Robert M. Davis Executive Vice President, Global Services, and Chief Financial Officer 991.7K 1.25M 2.43M 1.48M 1.09M 277.5K 7.52M 51.98% ↗
80 2016 Roger M. Perlmutter, M.D., Ph.D., Executive Vice President and President, Merck Research Laboratories 1.05M — 2.63M 1.60M 1.30M 519.9K 7.10M 59.51% ↗
81 2016 Roger M. Perlmutter, M.D., Ph.D. Executive Vice President and President, Merck Research Laboratories 1.05M — 2.63M 1.60M 1.30M 519.9K 7.10M 59.51% ↗
82 2016 Michael J. Holston, Executive Vice President and General Counsel 761.5K — 1.44M 880.0K 804.0K 443.1K 4.33M 53.64% ↗
83 2016 Michael J. Holston , Executive Vice President and General Counsel 761.5K — 1.44M 880.0K 804.0K 443.1K 4.33M 53.64% ↗
84 2015 Kenneth C. Frazier, Chairman, President and Chief Executive Officer 1.50M — 9.91M 4.80M 3.40M 4.59M 24.21M 60.78% ↗
85 2015 Roger M. Perlmutter, M.D., Ph.D. Executive Vice President and President, Merck Research Laboratories 1.02M — 3.34M 1.60M 1.95M 396.7K 8.30M 59.46% ↗
86 2015 Roger M. Perlmutter, M.D., Ph.D., Executive Vice President and President, Merck Research Laboratories 1.02M — 3.34M 1.60M 1.95M 396.7K 8.30M 59.46% ↗
87 2015 Adam H. Schechter, Executive Vice President and President, Global Human Health 976.5K — 3.31M 1.52M 1.56M 144.2K 7.51M 64.32% ↗
88 2015 Robert M. Davis, Executive Vice President and Chief Financial Officer 963.9K 1.25M 2.10M 1.40M 1.39M 209.3K 7.32M 47.88% ↗
89 2015 Robert M. Davis, Executive Vice President, Global Services and Chief Financial Officer 963.9K 1.25M 2.10M 1.40M 1.39M 209.3K 7.32M 47.88% ↗
90 2015 Robert M. Davis, Executive Vice President, Global Services, and Chief Financial Officer 963.9K 1.25M 2.10M 1.40M 1.39M 209.3K 7.32M 47.88% ↗
91 2015 Michael J. Holston , Executive Vice President and General Counsel 691.3K — 1.47M 800.0K 991.8K 238.5K 4.19M 54.18% ↗
92 2015 Michael J. Holston, Executive Vice President and General Counsel 691.3K — 1.47M 800.0K 991.8K 238.5K 4.19M 54.18% ↗
93 2014 Kenneth C. Frazier, Chairman, President and Chief Executive Officer 1.50M — 13.03M — 3.34M 197.4K 25.03M 52.04% ↗
94 2014 Kenneth C. Frazier, Chairman, President and Chief Executive Officer 1.50M — 13.03M 3.32M 3.34M 3.84M 25.03M 65.32% ↗
95 2014 Robert M. Davis, Executive Vice President and Chief Financial Officer 650.4K 2.50M 7.29M 1.16M 812.3K 342.0K 12.76M 66.27% ↗
96 2014 Robert M. Davis, Executive Vice President and Chief Financial Officer 650.4K 2.50M 7.29M — 812.3K 306.2K 12.76M 57.16% ↗
97 2014 Robert M. Davis, Executive Vice President, Global Services and Chief Financial Officer 650.4K 2.50M 7.29M 1.16M 812.3K 342.0K 12.76M 66.27% ↗
98 2014 Adam H. Schechter, Executive Vice President and President, Global Human Health 962.4K — 4.62M 1.26M 1.43M 2.05M 10.33M 57.00% ↗
99 2014 Adam H. Schechter, Executive Vice President Global Human Health 962.4K — 4.62M — 1.43M 104.0K 10.33M 44.77% ↗
100 2014 Roger M. Perlmutter, M.D., Ph.D., Executive Vice President and President, Merck Research Laboratories 1.00M 500.0K 3.54M 1.16M 1.77M 270.2K 8.24M 57.03% ↗
101 2014 Roger M. Perlmutter, M.D., Ph.D., Executive Vice President and Laboratories 1.00M 500.0K 3.54M — 1.77M 91.7K 8.24M 42.92% ↗
102 2014 Roger M. Perlmutter, M.D., Ph.D. Executive Vice President and President, Merck Research Laboratories 1.00M 500.0K 3.54M 1.16M 1.77M 270.2K 8.24M 57.03% ↗
103 2014 Bruce N. Kuhlik, Executive Vice President and General Counsel 807.5K — 2.80M — 1.04M 71.2K 6.17M 45.34% ↗
104 2014 Peter N. Kellogg, Former Executive Chief Financial Officer 381.9K — 3.89M — — 54.6K 5.39M 72.19% ↗
105 2013 Kenneth C. Frazier, Chairman, President and Chief Executive Officer 1.50M — 5.11M 4.00M 1.62M 1.15M 13.38M 68.07% ↗
106 2013 Kenneth C. Frazier, Chairman, President and Chief Executive Officer 1.50M — 5.11M — 1.62M 232.8K 13.38M 38.17% ↗
107 2013 Roger M. Perlmutter, M.D., Ph.D., Executive Vice President and President, Merck Research Laboratories 711.5K 500.0K 2.70M 1.40M 623.7K 50.9K 5.99M 68.49% ↗
108 2013 Roger M. Perlmutter, M.D., Ph.D., Executive Vice President and Laboratories 711.5K 500.0K 2.70M — 623.7K 16.5K 5.99M 45.10% ↗
109 2013 Adam H. Schechter, Executive Vice President Global Human Health 957.3K — 1.81M — 691.2K 160.4K 5.14M 35.27% ↗
110 2013 Adam H. Schechter, Executive Vice President and President, Global Human Health 957.3K — 1.81M 1.52M 691.2K 160.4K 5.14M 64.83% ↗
111 2013 Peter N. Kellogg, Former Executive Chief Financial Officer 988.9K — 1.57M — 611.2K 100.4K 4.90M 31.96% ↗
112 2013 Bruce N. Kuhlik, Executive Vice President and General Counsel 804.3K — 1.05M — 552.3K 86.5K 3.62M 29.01% ↗
113 2013 Peter N. Kellogg, Executive Vice Chief Financial Officer — — — — — — — — ↗
114 2013 Adam H. Schechter, Executive Vice President Human Health — — — — — — — — ↗
115 2013 Robert M. Davis, Executive Vice President and Chief Financial Officer — — — — — — — — ↗
116 2012 Kenneth C. Frazier, Chairman, President and Chief Executive Officer 1.50M — 3.28M — 2.50M 57.9K 15.46M 21.25% ↗
117 2012 Adam H. Schechter, Executive Vice President Global Human Health 938.9K — 1.86M — 1.25M 43.0K 7.73M 24.04% ↗
118 2012 Adam H. Schechter, Executive Vice President and President, Global Human Health 938.9K — 1.86M 1.52M 1.25M 43.0K 7.73M 43.71% ↗
119 2012 Peter S. Kim, Ph.D., Executive Vice President and President, Merck Research Laboratories 1.14M — 1.73M 1.20M 1.18M 58.4K 6.52M 44.87% ↗
120 2012 Peter N. Kellogg, Former Executive Chief Financial Officer 973.4K — 1.82M — 1.06M 19.3K 5.75M 31.65% ↗
121 2012 Peter N. Kellogg, Executive Vice President and Chief Financial Officer 973.4K — 1.82M 1.28M 1.06M 19.3K 5.75M 53.93% ↗
122 2012 Richard S. Bowles, III, Ph.D. Executive Vice President and Chief Ethics Compliance 218.1K — 164.0K — — 5.34M 5.72M 2.87% ↗
123 2012 Bruce N. Kuhlik, Executive Vice President and General Counsel 791.7K — 1.24M — 898.3K 21.3K 4.60M 26.88% ↗
124 2012 Roger M. Perlmutter, M.D., Ph.D., Executive Vice President and Laboratories — — — — — — — — ↗
125 2012 Robert M. Davis, Executive Vice President and Chief Financial Officer — — — — — — — — ↗
126 2012 Adam H. Schechter, Executive Vice President Human Health — — — — — — — — ↗
127 2012 Peter N. Kellogg, Executive Vice Chief Financial Officer — — — — — — — — ↗
128 2011 Richard T. Clark, Chairman of the Board 1.38M — 8.71M — 1.89M 43.9K 14.73M 59.16% ↗
129 2011 Raul E. Kohan, Executive Vice President 541.0K — 427.6K 400.0K — 6.95M 9.29M 8.91% ↗
130 2011 Adam H. Schechter, Executive Vice President and President, Global Human Health 906.3K — 1.36M 1.40M 1.35M 39.7K 6.54M 42.15% ↗
131 2011 Peter S. Kim, Ph.D., Executive Vice President and President, Merck Research Laboratories 1.11M — 1.49M 1.20M 1.29M 42.1K 5.99M 44.98% ↗
132 2011 Peter N. Kellogg, Executive Vice President and Chief Financial Officer 954.3K — 1.49M 1.28M 1.21M 19.0K 5.37M 51.52% ↗
133 2011 Bruce N. Kuhlik, Executive Vice President and General Counsel — — — — — — — — ↗
134 2011 Adam H. Schechter, Executive Vice President Human Health — — — — — — — — ↗
135 2011 Kenneth C. Frazier, Chairman, President and Chief Executive Officer — — — — — — — — ↗
136 2011 Peter N. Kellogg, Executive Vice Chief Financial Officer — — — — — — — — ↗
137 2011 Roger M. Perlmutter, M.D., Ph.D., Executive Vice President and Laboratories — — — — — — — — ↗
138 2011 Richard S. Bowles, III, Ph.D. Executive Vice President and Chief Ethics Compliance — — — — — — — — ↗
139 2010 Richard T. Clark, Chairman of the Board 1.86M — 7.08M 5.60M 3.31M 54.2K 24.57M 51.61% ↗
140 2010 Kenneth C. Frazier, President and Chief Executive Officer 1.16M — 2.35M 1.90M 2.15M 58.8K 9.44M 45.04% ↗
141 2010 Kenneth C. Frazier, Chairman, President and Chief Executive Officer 1.16M — 2.35M 1.90M 2.15M 58.8K 9.44M 45.04% ↗
142 2010 Peter S. Kim, Ph.D., Executive Vice President and President, Merck Research Laboratories 1.09M — 1.88M 1.50M 1.23M 30.9K 6.52M 51.90% ↗
143 2010 Peter N. Kellogg, Executive Vice President and Chief Financial Officer 934.9K — 1.93M 1.75M 1.15M 19.3K 6.14M 59.94% ↗
144 2010 Bruce N. Kuhlik, Executive Vice President and General Counsel 755.5K — 1.65M 1.47M 938.7K 21.0K 5.21M 59.99% ↗
145 2010 Richard S. Bowles, III, Ph.D. Executive Vice President and Chief Ethics Compliance — — — — — — — — ↗
146 2010 Adam H. Schechter, Executive Vice President and President, Global Human Health — — — — — — — — ↗
147 2010 Raul E. Kohan, Executive Vice President — — — — — — — — ↗
148 2009 Robert J. Bertolini, Former Executive Vice President and Chief Financial Officer 822.9K — 2.38M 2.03M — 29.84M 53.18M 8.29% ↗
149 2009 Fred Hassan, Former Chairman of the Board and Chief Executive Officer 1.47M — 7.81M 6.66M — 33.72M 49.65M 29.13% ↗
150 2009 Carrie S. Cox, Former Executive Vice President and President, Global Pharmaceuticals 931.0K — 2.38M 2.03M — 17.75M 32.30M 13.65% ↗
151 2009 Thomas P. Koestler, Ph.D., Former Executive Vice President and President, Schering-Plough Research Institute 730.1K — 1.89M 1.61M — 12.99M 24.56M 14.22% ↗
152 2009 Richard T. Clark, Chairman, President and Chief Executive Officer 1.80M — 4.38M 2.81M 2.85M 56.0K 16.84M 42.65% ↗
153 2009 Richard T. Clark, Chairman of the Board 1.80M — 3.35M 2.81M 2.85M 56.0K 15.81M 38.92% ↗
154 2009 Kenneth C. Frazier, Executive Vice President and President, Global Human Health 1.04M — 726.0K 1.07M 1.32M 55.9K 5.30M 33.94% ↗
155 2009 Kenneth C. Frazier, President and Chief Executive Officer 1.04M — 459.8K 1.07M 1.32M 55.9K 5.03M 30.45% ↗
156 2009 Kenneth C. Frazier, Chairman, President and Chief Executive Officer 1.04M — 459.8K 1.07M 1.32M 55.9K 5.03M 30.45% ↗
157 2009 Peter S. Kim, Ph.D., Executive Vice President and President, Merck Research Laboratories 1.07M — 367.8K 857.9K 1.11M 36.5K 3.93M 31.15% ↗
158 2009 Peter N. Kellogg, Executive Vice President and Chief Financial Officer 904.0K — 647.5K 358.5K 1.03M 404.9K 3.56M 28.24% ↗
159 2009 Bruce N. Kuhlik, Executive Vice President and General Counsel 706.2K — 524.6K 278.8K 805.9K 21.0K 2.53M 31.74% ↗
160 2009 Adam H. Schechter, Executive Vice President and President, Global Human Health — — — — — — — — ↗
161 2008 Richard T. Clark, Chairman, President and Chief Executive Officer 1.78M — 6.81M 6.41M 2.24M 73.7K 25.07M 52.72% ↗
162 2008 Richard T. Clark, Chairman of the Board 1.78M — 4.09M 6.41M 2.24M 73.7K 22.35M 46.96% ↗
163 2008 Fred Hassan, Former Chairman of the Board and Chief Executive Officer 1.72M — 5.48M 5.01M 3.39M 620.3K 18.14M 57.80% ↗
164 2008 Thomas P. Koestler, Ph.D., Former Executive Vice President and President, Schering-Plough Research Institute 811.3K — 5.92M 1.32M 786.4K 150.1K 9.51M 76.14% ↗
165 2008 Kenneth C. Frazier, Executive Vice President and President, Global Human Health 1.01M — 1.20M 2.63M 986.2K 127.9K 6.62M 57.77% ↗
166 2008 Carrie S. Cox, Former Executive Vice President and President, Global Pharmaceuticals 1.09M — 1.75M 1.62M 1.15M 172.9K 6.36M 52.92% ↗
167 2008 Kenneth C. Frazier, President and Chief Executive Officer 1.01M — 398.7K 2.63M 986.2K 127.9K 5.82M 51.98% ↗
168 2008 Robert J. Bertolini, Former Executive Vice President and Chief Financial Officer 960.3K — 1.69M 1.56M 1.01M 145.0K 5.52M 58.84% ↗
169 2008 Carrie S. Cox Executive Vice President President, Global Pharmaceuticals 1.09M — 599.31B — 1.15M 172.9K 4.98M 12,034,479.94% ↗
170 2008 Peter S. Kim, Ph.D., Executive Vice President and President, Merck Research Laboratories 1.03M — 1.28M 1.20M 875.0K 87.5K 4.75M 52.11% ↗
171 2008 Robert J. Bertolini Executive Vice President Chief Financial Officer 960.3K — 345.17B — 1.01M 145.0K 3.42M 10,083,287.64% ↗
172 2008 Peter N. Kellogg, Executive Vice President and Chief Financial Officer 873.6K — 691.1K 650.2K 721.6K 90.6K 3.17M 42.29% ↗
173 2008 Bruce N. Kuhlik, Executive Vice President and General Counsel 682.5K — 956.9K 650.2K 563.8K 22.7K 3.01M 53.37% ↗
174 2007 Fred Hassan Chairman of the Board & Chief Executive Officer 1.67M — 13.51M — — — 30.32M 44.55% ↗
175 2007 Fred Hassan, Former Chairman of the Board and Chief Executive Officer 1.67M — 8.83M 9.61M 4.03M 608.9K 26.26M 70.20% ↗
176 2007 Richard T. Clark, Chairman, President and Chief Executive Officer 1.62M — 5.30M 2.92M 4.31M 81.0K 19.10M 43.08% ↗
177 2007 Carrie S. Cox Executive Vice President & President, Global Pharmaceuticals 1.04M — 4.48M — — — 9.82M 45.61% ↗
178 2007 Carrie S. Cox, Former Executive Vice President and President, Global Pharmaceuticals 1.04M — 3.02M 3.26M 1.33M 249.7K 9.44M 66.52% ↗
179 2007 Robert J. Bertolini Executive Vice President & Chief Financial Officer 908.0K — 3.72M — — — 8.21M 45.34% ↗
180 2007 Robert J. Bertolini, Former Executive Vice President and Chief Financial Officer 908.0K — 2.56M 2.81M 1.18M 152.9K 8.16M 65.72% ↗
181 2007 Peter N. Kellogg, Executive Vice President and Chief Financial Officer 319.5K 150.0K 4.60M 2.43M 442.4K 42.7K 7.98M 88.04% ↗
182 2007 Kenneth C. Frazier, Executive Vice President and President, Global Human Health 876.3K — 2.51M 1.95M 1.63M 33.4K 7.52M 59.35% ↗
183 2007 Peter S. Kim, Ph.D., Executive Vice President and President, Merck Research Laboratories 922.6K — 2.62M 1.05M 1.40M 34.1K 6.28M 58.47% ↗
184 2007 Thomas P. Koestler, Ph.D., Former Executive Vice President and President, Schering-Plough Research Institute 726.3K — 1.77M 1.95M 828.3K 151.9K 5.86M 63.53% ↗
185 2007 Thomas P. Koestler, Ph.D. Executive Vice President & President, Schering-Plough Research Institute 726.3K — 1.91M — — — 5.35M 35.71% ↗
186 2007 Bruce N. Kuhlik, Executive Vice President and General Counsel — — — — — — — — ↗
187 2006 Fred Hassan Chairman of the Board & Chief Executive Officer 1.65M — 10.21M — — — 29.66M 34.42% ↗
188 2006 Carrie S. Cox Executive Vice President & President, Global Pharmaceuticals 987.5K — 3.57M — — — 11.31M 31.57% ↗
189 2006 Robert J. Bertolini Executive Vice President & Chief Financial Officer 858.7K — 2.96M — — — 9.90M 29.84% ↗
190 2006 Thomas J. Sabatino, Jr. Executive Vice President & General Counsel 711.1K — 2.49M — — — 7.28M 34.15% ↗
191 2006 Cecil B. Pickett, Ph.D. Former Senior Vice President & President, Schering-Plough Research Institute 506.0K — 2.14M — — — 6.79M 31.57% ↗
192 2006 Raul E. Kohan Senior Vice President and President, Animal Health 479.3K — 2.16M — — — 6.05M 35.66% ↗
193 2006 Thomas P. Koestler, Ph.D. Executive Vice President & President, Schering-Plough Research Institute 611.5K — 1.17M — — — 5.50M 21.21% ↗
194 2005 Fred Hassan Chairman of the Board Chief Executive Officer 1.56M 3.68M 4.14M 1.10M — 218.3K 12.76M 41.05% ↗
195 2005 Carrie S. Cox Executive Vice President President, Global Pharmaceuticals 937.5K 1.45M 1.57M 400.0K — 109.4K 4.71M 41.90% ↗
196 2005 Robert J. Bertolini Executive Vice President Chief Financial Officer 801.2K 1.08M 931.5K 250.0K — 88.4K 2.89M 40.86% ↗
197 2005 Cecil B. Pickett, Ph.D. Former Senior Vice President President, Schering-Plough Research Institute 733.4K 1.03M 852.8K 225.0K — 134.6K 2.62M 41.19% ↗
198 2005 Thomas J. Sabatino, Jr. 675.9K 909.7K 724.5K 200.0K — 78.5K 2.29M 40.33% ↗
CEO compensation breakdown

Proxy statements

Proxy statements (DEF 14A)
Filing date Form type Filing
2026-04-08 DEFA14A ↗
2026-04-08 DEF 14A ↗

Recent SEC filings

Recent SEC filings
Filing date Form type Filing
2026-05-07 4 ↗
2026-05-07 4 ↗
2026-05-07 4 ↗
2026-05-07 4 ↗
2026-05-07 4 ↗
2026-05-07 4 ↗
2026-05-07 4 ↗
2026-05-07 4 ↗
2026-05-07 4 ↗
2026-05-07 4 ↗

Executive team

NameTitleCompensationGender
Robert Davis Chairman, President & Chief Executive Officer 5M male
Dean Y. Li Executive Vice President & President of Merck Research Laboratories 3M —
Caroline Litchfield Executive Vice President & Chief Financial Officer 2M female
Betty D. Larson Executive Vice President & Chief Human Resources Officer 2M female
Jennifer L. Zachary Executive Vice President & General Counsel 2M female
Richard R. DeLuca Jr. Executive Vice President & President of Merck Animal Health 2M male
Sanat Chattopadhyay Executive Vice President & President of Merck Manufacturing Division 2M male
Chirfi Guindo Executive Vice President of Strategic Access, Policy & Communications 2M male
Eliav Barr Chief Medical Officer & Head of Global Clinical Development of Merck Research Laboratories — —
Joerg Koglin Senior VP & Head of General Medicine - Global Clinical Development — —
Johannes J. Oosthuizen Executive VP and President of Oncology & MSD International — male
Eric H. Rubin Senior Vice President of Global Clinical Oncology & Early-stage Oncology — —
ESG Rating
B+
DRUG MANUFACTURERS - GENERAL
2005
E (Environmental)
72.2 / 68.7
Company / Sector avg.
S (Social)
71.6 / 66.7
Company / Sector avg.
G (Governance)
73.5 / 67.9
Company / Sector avg.
ESG Total
72.4 / 67.7
Company / Sector avg.
ESG Score History DRUG MANUFACTURERS - GENERAL
Benchmark vs Sector
Political Trading Activity (25M)
Senate Trading Activity
Transaction Date Disclosed Senator State Owner Type Amount Link
2023-10-16 2023-11-16 Tommy Tuberville AL Joint Sale (Full) $1,001 - $15,000 ↗
2023-09-21 2023-10-20 Pete Ricketts NE Spouse Sale (Full) $50,001 - $100,000 ↗
2022-03-30 2022-04-08 Tommy Tuberville AL Joint Purchase $1,001 - $15,000 ↗
2021-03-29 2021-07-23 Tommy Tuberville AL Joint Sale (Full) $1,001 - $15,000 ↗
2020-04-16 2020-05-08 David Perdue — Joint Sale (Full) $1,001 - $15,000 ↗
2020-04-14 2021-05-02 David Perdue — Joint Sale (Partial) $50,001 - $100,000 ↗
2020-04-14 2020-05-08 David Perdue — Joint Sale (Full) $15,001 - $50,000 ↗
2020-04-07 2020-05-01 Kelly Loeffler GA Spouse Purchase $15,001 - $50,000 ↗
2020-04-06 2020-05-08 David Perdue — Joint Sale (Partial) $1,001 - $15,000 ↗
2020-04-03 2021-05-02 David Perdue — Joint Sale (Partial) $15,001 - $50,000 ↗
2020-03-31 2020-04-05 David Perdue — Joint Sale (Partial) $15,001 - $50,000 ↗
2020-02-05 2020-03-12 Kelly Loeffler GA Spouse Sale (Partial) $1,001 - $15,000 ↗
2020-02-05 2020-05-01 Kelly Loeffler GA Spouse Sale (Full) $1,001 - $15,000 ↗
2019-04-10 2019-05-07 David Perdue — Joint Sale (Partial) $15,001 - $50,000 ↗
2019-02-19 2019-03-06 David Perdue — Joint Sale (Partial) $15,001 - $50,000 ↗
2019-01-11 2019-01-17 James Inhofe OK Self Sale (Full) $100,001 - $250,000 ↗
2018-10-29 2018-11-08 David Perdue — Joint Sale (Partial) $1,001 - $15,000 ↗
2018-10-03 2018-11-08 David Perdue — Joint Sale (Partial) $15,001 - $50,000 ↗
2018-06-04 2018-07-10 Susan M. Collins ME Spouse Purchase $1,001 - $15,000 ↗
2018-04-24 2018-05-01 David Perdue — Joint Purchase $1,001 - $15,000 ↗
House Trading Activity
Transaction Date Disclosed Representative District Owner Type Amount Link
2026-02-04 2026-03-17 Josh Gottheimer NJ05 Joint Purchase $1,001 - $15,000 ↗
2026-01-13 2026-02-12 Michael McCaul TX10 Spouse Sale $15,001 - $50,000 ↗
2025-12-19 2026-01-12 Gilbert Cisneros CA31 — Purchase $1,001 - $15,000 ↗
2025-12-18 2026-01-16 Julie Johnson TX32 Joint Sale $1,001 - $15,000 ↗
2025-11-18 2025-12-15 Gilbert Cisneros CA31 — Purchase $1,001 - $15,000 ↗
2025-11-13 2025-12-12 Julie Johnson TX32 Joint Sale $1,001 - $15,000 ↗
2025-09-29 2025-10-03 Ro Khanna CA17 — Sale $1,001 - $15,000 ↗
2025-09-23 2025-10-10 Valerie Hoyle OR04 Spouse Sale (Full) $1,001 - $15,000 ↗
2025-08-28 2025-09-01 Marjorie Taylor Greene GA14 — Purchase $1,001 - $15,000 ↗
2025-08-14 2025-09-12 Julie Johnson TX32 Joint Sale $1,001 - $15,000 ↗
2025-08-05 2025-09-12 Gilbert Cisneros CA31 — Purchase $1,001 - $15,000 ↗
2025-08-04 2025-09-15 Lisa McClain MI09 Spouse Sale $1,001 - $15,000 ↗
2025-07-11 2025-08-20 Ritchie Torres NY15 — Sale (Full) $1,001 - $15,000 ↗
2025-06-24 2025-08-13 Lisa McClain MI09 Spouse Purchase $1,001 - $15,000 ↗
2025-06-16 2025-07-15 Scott Mr Franklin FL18 Joint Sale $1,001 - $15,000 ↗
2025-06-13 2025-07-15 Julie Johnson TX32 Joint Purchase $1,001 - $15,000 ↗
2025-05-30 2025-06-06 Gilbert Cisneros CA31 — Sale (Full) $1,001 - $15,000 ↗
2025-05-30 2025-06-09 Gilbert Cisneros CA31 — Sale $1,001 - $15,000 ↗
2025-05-19 2025-06-12 Michael McCaul TX10 Spouse Purchase $50,001 - $100,000 ↗
2025-05-15 2025-06-02 Rob Bresnahan PA08 — Sale $15,001 - $50,000 ↗
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Drug Manufacturers - General